https://trial.medpath.com/news/brexu-cel-yields-high-response-rates-in-relapsed-refractory-btk-naive-mcl 2024-12-22T18:39:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brexu-cel-yields-high-response-rates-in-relapsed-refractory-btk-naive-mcl 2024-12-22T18:39:37+00:00 weekly 0.7 https://trial.medpath.com/news/ongoing-research-seeks-to-optimize-targeted-therapy-use-in-mcrc-onclive 2024-12-22T17:08:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ongoing-research-seeks-to-optimize-targeted-therapy-use-in-mcrc-onclive 2024-12-22T17:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/x-ray-brachytherapy-sustains-organ-preservation-in-early-rectal-cancer 2024-12-22T17:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/x-ray-brachytherapy-sustains-organ-preservation-in-early-rectal-cancer 2024-12-22T17:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/selective-antisense-oligonucleotide-based-jak2-inhibitor-receives-fda-orphan-drug 2024-12-22T16:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/selective-antisense-oligonucleotide-based-jak2-inhibitor-receives-fda-orphan-drug 2024-12-22T16:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-shows-long-term-vision-benefits-in-rare-eye-disease-medpage-today 2024-12-22T15:55:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-shows-long-term-vision-benefits-in-rare-eye-disease-medpage-today 2024-12-22T15:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/vivani-medical-strategic-innovation-in-glp-1-obesity-treatment-justifies-buy-rating 2024-12-22T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivani-medical-strategic-innovation-in-glp-1-obesity-treatment-justifies-buy-rating 2024-12-22T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/bioa-alert-the-investigation-on-behalf-of-bioage-labs-globenewswire 2024-12-22T12:46:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioa-alert-the-investigation-on-behalf-of-bioage-labs-globenewswire 2024-12-22T12:46:27+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-congress-drops-pbm-reform-from-year-end-funding-package-despite-bipartisan-support 2024-12-22T12:15:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-congress-drops-pbm-reform-from-year-end-funding-package-despite-bipartisan-support 2024-12-22T12:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-brolucizumab-and-aflibercept-for-treating-dme-modern-retina 2024-12-22T11:47:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparison-of-brolucizumab-and-aflibercept-for-treating-dme-modern-retina 2024-12-22T11:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/positive-clinical-trial-results-highlighted-in-recent-pharma-developments 2024-12-22T11:13:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-clinical-trial-results-highlighted-in-recent-pharma-developments 2024-12-22T11:13:12+00:00 weekly 0.7 https://trial.medpath.com/news/prothena-s-parkinson-s-drug-fails-primary-endpoint-but-sparks-investor-interest 2024-12-22T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prothena-s-parkinson-s-drug-fails-primary-endpoint-but-sparks-investor-interest 2024-12-22T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/higher-ferritin-threshold-of-25mg-l-proves-cost-effective-for-iron-deficiency-screening-in-women 2024-12-22T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/higher-ferritin-threshold-of-25mg-l-proves-cost-effective-for-iron-deficiency-screening-in-women 2024-12-22T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-tmb-levels-impact-immunotherapy-outcomes-in-breast-cancer-treatment 2024-12-22T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-tmb-levels-impact-immunotherapy-outcomes-in-breast-cancer-treatment 2024-12-22T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/implementation-of-a-parent-training-intervention-sparck-to-prevent-childhood-mental-trials 2024-12-22T05:31:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implementation-of-a-parent-training-intervention-sparck-to-prevent-childhood-mental-trials 2024-12-22T05:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/research-shows-guillain-barre-syndrome-remains-rare-among-older-adults-after-rsv-vaccination 2024-12-22T04:36:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-shows-guillain-barre-syndrome-remains-rare-among-older-adults-after-rsv-vaccination 2024-12-22T04:36:02+00:00 weekly 0.7 https://trial.medpath.com/news/prior-car-t-cell-therapy-exposure-may-impact-odronextamab-benefit-in-dlbcl 2024-12-22T03:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prior-car-t-cell-therapy-exposure-may-impact-odronextamab-benefit-in-dlbcl 2024-12-22T03:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/thousands-of-women-with-breast-cancer-may-soon-be-told-they-don-t-need-any-treatment 2024-12-22T02:22:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thousands-of-women-with-breast-cancer-may-soon-be-told-they-don-t-need-any-treatment 2024-12-22T02:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-premarket-approval-application-for-oraquick-hiv-self-test-expanding 2024-12-22T02:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-premarket-approval-application-for-oraquick-hiv-self-test-expanding 2024-12-22T02:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/hervolution-therapeutics-dark-genome-biotech-company-raises-11-7-million-series-a 2024-12-22T01:47:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hervolution-therapeutics-dark-genome-biotech-company-raises-11-7-million-series-a 2024-12-22T01:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/aim-weekly-movers-potential-resurrection-for-active-energy-uk-investor-magazine 2024-12-22T01:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aim-weekly-movers-potential-resurrection-for-active-energy-uk-investor-magazine 2024-12-22T01:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zepbound-for-sleep-apnea-yahoo 2024-12-22T00:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zepbound-for-sleep-apnea-yahoo 2024-12-22T00:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-pembrolizumab-regimen-upholds-survival-benefit-in-resectable-nsclc 2024-12-21T23:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-pembrolizumab-regimen-upholds-survival-benefit-in-resectable-nsclc 2024-12-21T23:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/could-mosquitoes-deliver-vaccines-against-malaria-health-news-al-jazeera 2024-12-21T20:26:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-mosquitoes-deliver-vaccines-against-malaria-health-news-al-jazeera 2024-12-21T20:26:27+00:00 weekly 0.7 https://trial.medpath.com/news/jefferies-sees-novo-dropping-at-least-10-15-on-obesity-data-yahoo-finance 2024-12-21T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jefferies-sees-novo-dropping-at-least-10-15-on-obesity-data-yahoo-finance 2024-12-21T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/news/gholam-contrasts-lenvatinib-with-other-options-in-child-pugh-b-hcc-targeted-oncology 2024-12-21T18:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gholam-contrasts-lenvatinib-with-other-options-in-child-pugh-b-hcc-targeted-oncology 2024-12-21T18:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-group-aim-avct-leading-the-way-in-precision-cancer-therapies-share-talk 2024-12-21T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-group-aim-avct-leading-the-way-in-precision-cancer-therapies-share-talk 2024-12-21T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/news/achieving-a-2-67x-reduction-in-study-build-time-for-an-innovative-neuromodulation-study 2024-12-21T16:00:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/achieving-a-2-67x-reduction-in-study-build-time-for-an-innovative-neuromodulation-study 2024-12-21T16:00:49+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-perspective-on-drugs-for-duchenne-muscular-dystrophy-proposals-for-better 2024-12-21T15:03:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-perspective-on-drugs-for-duchenne-muscular-dystrophy-proposals-for-better 2024-12-21T15:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/yoltech-therapeutics-announces-successful-completion-of-dose-escalation-phase-in 2024-12-21T14:45:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yoltech-therapeutics-announces-successful-completion-of-dose-escalation-phase-in 2024-12-21T14:45:03+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-mrna-car-therapy-mt-303-under-study-for-liver-cancer-targeted-oncology 2024-12-21T13:59:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-mrna-car-therapy-mt-303-under-study-for-liver-cancer-targeted-oncology 2024-12-21T13:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-issues-audited-financial-statements-completes-globenewswire 2024-12-21T09:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-issues-audited-financial-statements-completes-globenewswire 2024-12-21T09:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharma-s-imcivree-wins-fda-approval-for-rare-obesity-treatment-in-young-children 2024-12-21T09:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rhythm-pharma-s-imcivree-wins-fda-approval-for-rare-obesity-treatment-in-young-children 2024-12-21T09:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/polyrizon-inks-manufacturing-agreement-for-its-pl-14-allergy-blocker-with-eurofins-cdmo 2024-12-21T08:32:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polyrizon-inks-manufacturing-agreement-for-its-pl-14-allergy-blocker-with-eurofins-cdmo 2024-12-21T08:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-transplant-eligibility-expand-treatment-options-for-secondary-aml-patients 2024-12-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-transplant-eligibility-expand-treatment-options-for-secondary-aml-patients 2024-12-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-encorafenib-plus-cetuximab-and-chemo-for-braf-onclive 2024-12-21T06:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-encorafenib-plus-cetuximab-and-chemo-for-braf-onclive 2024-12-21T06:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-alhemo-r-injection-as-once-daily-prophylactic-treatment-to-prevent-or-pr-newswire 2024-12-21T06:43:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-alhemo-r-injection-as-once-daily-prophylactic-treatment-to-prevent-or-pr-newswire 2024-12-21T06:43:15+00:00 weekly 0.7 https://trial.medpath.com/news/belapectin-misses-primary-endpoint-in-phase-3-mash-cirrhosis-portal-hypertension-trial 2024-12-21T05:29:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belapectin-misses-primary-endpoint-in-phase-3-mash-cirrhosis-portal-hypertension-trial 2024-12-21T05:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-leaders-call-for-value-based-cancer-care-reform-to-address-cost-and-access-barriers 2024-12-21T05:26:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-leaders-call-for-value-based-cancer-care-reform-to-address-cost-and-access-barriers 2024-12-21T05:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/breaking-health-news-landmark-case-drug-developments-and-legal-battles 2024-12-21T05:02:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breaking-health-news-landmark-case-drug-developments-and-legal-battles 2024-12-21T05:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-obesity-drug-zepbound-approved-to-treat-sleep-apnea-in-u-s-stat-news 2024-12-21T05:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-obesity-drug-zepbound-approved-to-treat-sleep-apnea-in-u-s-stat-news 2024-12-21T05:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/global-standardization-of-tils-assessment-marks-major-progress-in-breast-cancer-research 2024-12-21T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-standardization-of-tils-assessment-marks-major-progress-in-breast-cancer-research 2024-12-21T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/critics-condemn-new-uk-puberty-blockers-clinical-trial-as-unethical-the-christian-institute 2024-12-21T03:42:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/critics-condemn-new-uk-puberty-blockers-clinical-trial-as-unethical-the-christian-institute 2024-12-21T03:42:27+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-iv-thrombolysis-with-alteplase-in-patients-with-vessel-occlusion-in-the-wake-up-trial 2024-12-21T02:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-iv-thrombolysis-with-alteplase-in-patients-with-vessel-occlusion-in-the-wake-up-trial 2024-12-21T02:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/sorriso-pharma-s-uc-treatment-hits-phase-ib-endpoints-clinical-trials-arena 2024-12-21T02:14:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sorriso-pharma-s-uc-treatment-hits-phase-ib-endpoints-clinical-trials-arena 2024-12-21T02:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/factors-associated-with-male-recruitment-in-a-multi-site-randomized-behavioral-clinical-trial 2024-12-21T01:35:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/factors-associated-with-male-recruitment-in-a-multi-site-randomized-behavioral-clinical-trial 2024-12-21T01:35:52+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-nsclc-content-for-2024-american-journal-of-managed-care 2024-12-21T01:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-nsclc-content-for-2024-american-journal-of-managed-care 2024-12-21T01:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/an-open-letter-to-dennis-j-selkoe-m-d-alzforum 2024-12-21T00:18:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-open-letter-to-dennis-j-selkoe-m-d-alzforum 2024-12-21T00:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/asymptomatic-brain-metastases-in-egfr-mutant-nsclc-medpage-today 2024-12-20T22:01:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asymptomatic-brain-metastases-in-egfr-mutant-nsclc-medpage-today 2024-12-20T22:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-announces-receipt-of-complete-response-letter-for-zynquistatm-sotagliflozin 2024-12-20T21:35:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-announces-receipt-of-complete-response-letter-for-zynquistatm-sotagliflozin 2024-12-20T21:35:25+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-announces-u-s-fda-approval-for-trikafta-elexacaftor-tezacaftor-ivacaftor-and 2024-12-20T20:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-announces-u-s-fda-approval-for-trikafta-elexacaftor-tezacaftor-ivacaftor-and 2024-12-20T20:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/endevica-bio-advances-tcmcb07-to-phase-2-trial-for-preventing-chemotherapy-induced-weight-loss 2024-12-20T20:38:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endevica-bio-advances-tcmcb07-to-phase-2-trial-for-preventing-chemotherapy-induced-weight-loss 2024-12-20T20:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman-biospace 2024-12-20T20:38:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-appoints-john-h-johnson-as-executive-chairman-biospace 2024-12-20T20:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/blackstone-acquisition-of-clinical-trial-service-provider-not-opposed-subject-to-divestiture-of 2024-12-20T20:37:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blackstone-acquisition-of-clinical-trial-service-provider-not-opposed-subject-to-divestiture-of 2024-12-20T20:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/1-big-new-green-flag-for-crispr-therapeutics-stock-the-globe-and-mail 2024-12-20T19:26:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1-big-new-green-flag-for-crispr-therapeutics-stock-the-globe-and-mail 2024-12-20T19:26:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-humacyte-s-lab-grown-blood-vessels-in-milestone-for-regenerative-medicine 2024-12-20T19:11:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-humacyte-s-lab-grown-blood-vessels-in-milestone-for-regenerative-medicine 2024-12-20T19:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/one-year-in-cancer-research-and-much-to-celebrate-nci 2024-12-20T18:59:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/one-year-in-cancer-research-and-much-to-celebrate-nci 2024-12-20T18:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-launches-first-phase-iii-lsd-trial-a-new-psychedelic-mushroom-species 2024-12-20T18:58:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-launches-first-phase-iii-lsd-trial-a-new-psychedelic-mushroom-species 2024-12-20T18:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/filling-unmet-needs-in-scac-is-key-as-incidence-rates-are-rising-onclive 2024-12-20T18:23:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/filling-unmet-needs-in-scac-is-key-as-incidence-rates-are-rising-onclive 2024-12-20T18:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/primo-biotechnology-partners-with-antelope-surgical-solutions-for-first-fda-approved 2024-12-20T18:06:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primo-biotechnology-partners-with-antelope-surgical-solutions-for-first-fda-approved 2024-12-20T18:06:40+00:00 weekly 0.7 https://trial.medpath.com/news/the-kids-are-alright-miebo-and-xdemvy-at-year-1-healio 2024-12-20T17:49:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-kids-are-alright-miebo-and-xdemvy-at-year-1-healio 2024-12-20T17:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/gates-institute-s-top-stories-of-2024 2024-12-20T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gates-institute-s-top-stories-of-2024 2024-12-20T17:48:06+00:00 weekly 0.7 https://trial.medpath.com/news/using-data-patterns-to-proactively-improve-study-quality-applied-clinical-trials 2024-12-20T17:45:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/using-data-patterns-to-proactively-improve-study-quality-applied-clinical-trials 2024-12-20T17:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/cms-proposes-medicare-coverage-for-transcatheter-tricuspid-replacement-medtech-dive 2024-12-20T17:36:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cms-proposes-medicare-coverage-for-transcatheter-tricuspid-replacement-medtech-dive 2024-12-20T17:36:02+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-s-device-to-treat-inflammation-in-esrd-receives-fda-breakthrough-designation 2024-12-20T17:33:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-s-device-to-treat-inflammation-in-esrd-receives-fda-breakthrough-designation 2024-12-20T17:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/jcr-pharmaceuticals-initiates-phase-iii-clinical-trial-of-jr-142-in-japan-a-long-yahoo-finance 2024-12-20T17:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-initiates-phase-iii-clinical-trial-of-jr-142-in-japan-a-long-yahoo-finance 2024-12-20T17:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-ibrutinib-in-early-stage-chronic-lymphocytic-leukemia-the-asco-post 2024-12-20T17:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/use-of-ibrutinib-in-early-stage-chronic-lymphocytic-leukemia-the-asco-post 2024-12-20T17:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/discussion-trial-to-prevent-multidrug-resistant-tb-in-kids-enca 2024-12-20T17:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/discussion-trial-to-prevent-multidrug-resistant-tb-in-kids-enca 2024-12-20T17:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/updated-mcdonald-criteria-ushers-in-new-era-for-multiple-sclerosis-diagnosis 2024-12-20T17:00:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-mcdonald-criteria-ushers-in-new-era-for-multiple-sclerosis-diagnosis 2024-12-20T17:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-study-revolutionizes-osteosarcoma-care-mirage-news 2024-12-20T16:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-study-revolutionizes-osteosarcoma-care-mirage-news 2024-12-20T16:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/curacle-presents-results-of-its-phase-2a-clinical-trial-of-cu06-for-dme 2024-12-20T15:57:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curacle-presents-results-of-its-phase-2a-clinical-trial-of-cu06-for-dme 2024-12-20T15:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-mash-miss-sends-galectin-stock-tumbling-biospace 2024-12-20T15:40:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-mash-miss-sends-galectin-stock-tumbling-biospace 2024-12-20T15:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-investigate-potential-treatment-for-eliminating-hiv-from-the-brain 2024-12-20T15:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-investigate-potential-treatment-for-eliminating-hiv-from-the-brain 2024-12-20T15:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-trials-should-emphasize-transparency-not-secrecy-stat-news 2024-12-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-trials-should-emphasize-transparency-not-secrecy-stat-news 2024-12-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/zejula-jemperli-combo-shows-promising-responses-in-breast-cancer-subset-cure-today 2024-12-20T14:36:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zejula-jemperli-combo-shows-promising-responses-in-breast-cancer-subset-cure-today 2024-12-20T14:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/roivios-wins-fda-ide-for-renal-assist-device-massdevice 2024-12-20T14:22:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roivios-wins-fda-ide-for-renal-assist-device-massdevice 2024-12-20T14:22:15+00:00 weekly 0.7 https://trial.medpath.com/news/merit-medical-announces-fda-approval-of-the-wrapsody-cell-impermeable-endoprosthesis 2024-12-20T14:19:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merit-medical-announces-fda-approval-of-the-wrapsody-cell-impermeable-endoprosthesis 2024-12-20T14:19:21+00:00 weekly 0.7 https://trial.medpath.com/news/cansino-biologics-inc-announces-initiation-of-phase-iii-clinical-trial-and-completion-of-first 2024-12-20T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cansino-biologics-inc-announces-initiation-of-phase-iii-clinical-trial-and-completion-of-first 2024-12-20T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/cansino-biologics-inc-announces-initiation-of-phase-ii-iii-clinical-trial-and-marketscreener 2024-12-20T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cansino-biologics-inc-announces-initiation-of-phase-ii-iii-clinical-trial-and-marketscreener 2024-12-20T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/aridis-pharmaceuticals-provides-corporate-update-on-clinical-developments-and-financial-strategy 2024-12-20T14:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aridis-pharmaceuticals-provides-corporate-update-on-clinical-developments-and-financial-strategy 2024-12-20T14:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-strategies-evolve-for-hr-her2-metastatic-breast-cancer-experts-weigh-in-on-site-specific-approaches 2024-12-20T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-strategies-evolve-for-hr-her2-metastatic-breast-cancer-experts-weigh-in-on-site-specific-approaches 2024-12-20T14:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-provides-update-on-the-ability-of-its-hemopurifier-r-to-capture-h5n1-bird-flu 2024-12-20T14:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aethlon-medical-provides-update-on-the-ability-of-its-hemopurifier-r-to-capture-h5n1-bird-flu 2024-12-20T14:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/braincool-ab-publ-adds-two-centers-to-the-cottis-2-clinical-study-of-its-cooling-systems-in 2024-12-20T13:26:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/braincool-ab-publ-adds-two-centers-to-the-cottis-2-clinical-study-of-its-cooling-systems-in 2024-12-20T13:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/apollomics-phase-3-trial-in-china-shows-no-benefit-investing-com 2024-12-20T13:16:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apollomics-phase-3-trial-in-china-shows-no-benefit-investing-com 2024-12-20T13:16:53+00:00 weekly 0.7 https://trial.medpath.com/news/rad-202-receives-approval-to-start-phase-1-therapeutic-trial-stock-titan 2024-12-20T13:13:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rad-202-receives-approval-to-start-phase-1-therapeutic-trial-stock-titan 2024-12-20T13:13:49+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-cancer-research-program-drives-breakthrough-discoveries-with-50m-funding-boost 2024-12-20T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-cancer-research-program-drives-breakthrough-discoveries-with-50m-funding-boost 2024-12-20T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nosedives-on-underwhelming-cagrisema-phase-iii-weight-loss-data-biospace 2024-12-20T12:59:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nosedives-on-underwhelming-cagrisema-phase-iii-weight-loss-data-biospace 2024-12-20T12:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/translating-molecular-analysis-of-brain-tumors-into-patient-treatment-mayo-clinic 2024-12-20T12:46:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/translating-molecular-analysis-of-brain-tumors-into-patient-treatment-mayo-clinic 2024-12-20T12:46:44+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-shares-surge-38-on-fda-approval-of-symvess-morningstar 2024-12-20T12:28:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-shares-surge-38-on-fda-approval-of-symvess-morningstar 2024-12-20T12:28:04+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-receives-approval-of-dovbleron-r-taletrectinib-adipate-capsule-ros1 2024-12-20T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-receives-approval-of-dovbleron-r-taletrectinib-adipate-capsule-ros1 2024-12-20T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-announces-first-patient-dosed-in-phase-2-clinical-study-for-its-lead-pr-newswire 2024-12-20T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marengo-announces-first-patient-dosed-in-phase-2-clinical-study-for-its-lead-pr-newswire 2024-12-20T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-advances-anticoagulant-antibody-pair-to-late-stage-testing-firstword-pharma 2024-12-20T12:22:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-advances-anticoagulant-antibody-pair-to-late-stage-testing-firstword-pharma 2024-12-20T12:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-sanofi-acquired-rights-to-develop-and-commercialize-aficamten-in 2024-12-20T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-announces-sanofi-acquired-rights-to-develop-and-commercialize-aficamten-in 2024-12-20T11:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-future-prospects-and-investment-considerations 2024-12-20T11:34:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-therapeutics-future-prospects-and-investment-considerations 2024-12-20T11:34:00+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cells-head-to-the-clinic-treatments-for-cancer-diabetes-and-parkinson-s-disease-could 2024-12-20T11:19:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cells-head-to-the-clinic-treatments-for-cancer-diabetes-and-parkinson-s-disease-could 2024-12-20T11:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/fennec-s-pedmarqsi-r-breakthrough-first-nhs-treatment-for-child-cancer-related-hearing-loss 2024-12-20T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fennec-s-pedmarqsi-r-breakthrough-first-nhs-treatment-for-child-cancer-related-hearing-loss 2024-12-20T11:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/antibiotics-do-not-increase-risks-for-cognitive-decline-dementia-in-older-adults-new-data-says 2024-12-20T11:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibiotics-do-not-increase-risks-for-cognitive-decline-dementia-in-older-adults-new-data-says 2024-12-20T11:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/summary-report-on-authorisation-lytgobi-r-swissmedic 2024-12-20T10:39:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summary-report-on-authorisation-lytgobi-r-swissmedic 2024-12-20T10:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate-against-biospace 2024-12-20T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/limmatech-awarded-fda-fast-track-designation-for-vaccine-candidate-against-biospace 2024-12-20T10:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/hot-stocks-exosome-breakthrough-gas-pipeline-deals-and-more-sharecafe 2024-12-20T10:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hot-stocks-exosome-breakthrough-gas-pipeline-deals-and-more-sharecafe 2024-12-20T10:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-mixed-findings-from-ovarian-cancer-phase-iii-study-shares-magazine 2024-12-20T09:00:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-reports-mixed-findings-from-ovarian-cancer-phase-iii-study-shares-magazine 2024-12-20T09:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/synairgen-backer-ready-to-pump-ps18-ps19-million-into-phase-ii-trial-aim-sng-otc-syggf 2024-12-20T08:41:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synairgen-backer-ready-to-pump-ps18-ps19-million-into-phase-ii-trial-aim-sng-otc-syggf 2024-12-20T08:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/a-venture-firm-breathes-new-life-into-an-old-ngm-drug-biopharma-dive 2024-12-20T08:29:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-venture-firm-breathes-new-life-into-an-old-ngm-drug-biopharma-dive 2024-12-20T08:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/oncodesign-precision-medicine-reacquires-rights-to-its-opm-201-program-from-servier 2024-12-20T07:59:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncodesign-precision-medicine-reacquires-rights-to-its-opm-201-program-from-servier 2024-12-20T07:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-2-pilot-study-of-umbilical-cord-blood-infusion-as-an-adjuvant-consolidation-therapy 2024-12-20T07:58:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-2-pilot-study-of-umbilical-cord-blood-infusion-as-an-adjuvant-consolidation-therapy 2024-12-20T07:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/novel-mri-biomarker-shows-promise-for-early-detection-of-heart-damage-in-duchenne-muscular-dystrophy 2024-12-20T07:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-mri-biomarker-shows-promise-for-early-detection-of-heart-damage-in-duchenne-muscular-dystrophy 2024-12-20T07:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-sirna-therapy-fitusiran-in-combination-with-antithrombin-modulation-for-hemophilia 2024-12-20T07:14:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-sirna-therapy-fitusiran-in-combination-with-antithrombin-modulation-for-hemophilia 2024-12-20T07:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/crism-therapeutics-partners-with-aixial-group-for-phase-2-glioblastoma-trial-tipranks 2024-12-20T07:09:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crism-therapeutics-partners-with-aixial-group-for-phase-2-glioblastoma-trial-tipranks 2024-12-20T07:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-treatments-transform-landscape-for-rare-hemolytic-anemias-from-c5-inhibitors-to-novel-therapeutic-approaches 2024-12-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-treatments-transform-landscape-for-rare-hemolytic-anemias-from-c5-inhibitors-to-novel-therapeutic-approaches 2024-12-20T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inflarx-announces-first-patient-dosed-in-phase-2a-study-for-csu-and-hs 2024-12-20T06:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflarx-announces-first-patient-dosed-in-phase-2a-study-for-csu-and-hs 2024-12-20T06:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-therapy-shows-promise-in-earlier-treatment-lines-for-relapsed-refractory-multiple-myeloma 2024-12-20T06:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-therapy-shows-promise-in-earlier-treatment-lines-for-relapsed-refractory-multiple-myeloma 2024-12-20T06:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-advances-in-lung-cancer-treatment-immunotherapy-adcs-and-equity-in-care 2024-12-20T05:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-highlight-advances-in-lung-cancer-treatment-immunotherapy-adcs-and-equity-in-care 2024-12-20T05:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/onward-medical-receives-fda-de-novo-classification-and-us-globenewswire 2024-12-20T04:59:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onward-medical-receives-fda-de-novo-classification-and-us-globenewswire 2024-12-20T04:59:59+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-begins-phase-3-cove-study-for-covid-19-mrna-vaccine 2024-12-20T04:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-begins-phase-3-cove-study-for-covid-19-mrna-vaccine 2024-12-20T04:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/engene-reports-full-year-2024-financial-results-and-provides-a-business-update 2024-12-20T04:07:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engene-reports-full-year-2024-financial-results-and-provides-a-business-update 2024-12-20T04:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/limited-treatment-options-highlight-critical-role-of-rsv-prevention-in-high-risk-adults 2024-12-20T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/limited-treatment-options-highlight-critical-role-of-rsv-prevention-in-high-risk-adults 2024-12-20T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stemcyte-announces-successful-phase-iia-clinical-trial-results-for-hpc-cord-blood-in 2024-12-20T03:58:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stemcyte-announces-successful-phase-iia-clinical-trial-results-for-hpc-cord-blood-in 2024-12-20T03:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-announces-fda-approval-of-symvesstm-acellular-globenewswire 2024-12-20T03:49:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-announces-fda-approval-of-symvesstm-acellular-globenewswire 2024-12-20T03:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/vunakizumab-shows-promise-in-treating-active-ankylosing-spondylitis-in-phase-2-3-study 2024-12-20T03:41:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vunakizumab-shows-promise-in-treating-active-ankylosing-spondylitis-in-phase-2-3-study 2024-12-20T03:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-interim-results-on-abrocitinib-for-adolescents-adults-with-atopic-dermatitis 2024-12-20T03:14:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-highlights-interim-results-on-abrocitinib-for-adolescents-adults-with-atopic-dermatitis 2024-12-20T03:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-announces-positive-u-s-clinical-data-from-globenewswire 2024-12-20T02:38:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-announces-positive-u-s-clinical-data-from-globenewswire 2024-12-20T02:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/vanderbilt-researchers-achieve-milestone-in-alzheimer-s-drug-development-news-medical 2024-12-20T01:45:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanderbilt-researchers-achieve-milestone-in-alzheimer-s-drug-development-news-medical 2024-12-20T01:45:09+00:00 weekly 0.7 https://trial.medpath.com/news/irregular-assessment-times-in-pragmatic-randomized-clinical-trials-biomed-central 2024-12-20T01:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irregular-assessment-times-in-pragmatic-randomized-clinical-trials-biomed-central 2024-12-20T01:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/igc-pharma-to-participate-in-biopartnering-at-jpm-alongside-j-p-morgan-healthcare-conference-2025 2024-12-20T00:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/igc-pharma-to-participate-in-biopartnering-at-jpm-alongside-j-p-morgan-healthcare-conference-2025 2024-12-20T00:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/b-riley-upgrades-cognition-therapeutics-to-buy-following-positive-lewy-bodies-data 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/b-riley-upgrades-cognition-therapeutics-to-buy-following-positive-lewy-bodies-data 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gozetotide-shows-promise-in-psma-positive-prostate-cancer-diagnosis-and-treatment 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gozetotide-shows-promise-in-psma-positive-prostate-cancer-diagnosis-and-treatment 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novos-cagrisema-disappoints-in-pivotal-trial 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novos-cagrisema-disappoints-in-pivotal-trial 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-conducts-clinical-trials-to-improve-prostate-cancer-treatment 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsf-conducts-clinical-trials-to-improve-prostate-cancer-treatment 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-review-of-lupus-nephritis-randomized-controlled-trials-highlights-evidence-gaps-and-under-represented-populations 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-review-of-lupus-nephritis-randomized-controlled-trials-highlights-evidence-gaps-and-under-represented-populations 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-targets-rare-obesity-disorders-with-promising-treatments 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-targets-rare-obesity-disorders-with-promising-treatments 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/akamis-bio-secures-60-million-for-cancer-gene-therapy-development-and-partners-with-xuanzhu-biopharma 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akamis-bio-secures-60-million-for-cancer-gene-therapy-development-and-partners-with-xuanzhu-biopharma 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-shows-promise-for-ebv-driven-post-transplant-lymphoproliferative-disease 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-shows-promise-for-ebv-driven-post-transplant-lymphoproliferative-disease 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-issues-2025-financial-outlook-and-other-pharma-updates 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-issues-2025-financial-outlook-and-other-pharma-updates 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sotagliflozin-may-lower-hba1c-without-raising-risks-for-adults-with-type-1-diabetes-ckd 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotagliflozin-may-lower-hba1c-without-raising-risks-for-adults-with-type-1-diabetes-ckd 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-trial-of-mrna-vaccine-for-norovirus-underway-amid-surge-in-cases 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-trial-of-mrna-vaccine-for-norovirus-underway-amid-surge-in-cases 2024-12-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-year-in-drugs-boulder-weekly 2024-12-19T23:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-year-in-drugs-boulder-weekly 2024-12-19T23:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/abortion-law-changes-could-threaten-women-s-participation-in-us-clinical-trials 2024-12-19T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abortion-law-changes-could-threaten-women-s-participation-in-us-clinical-trials 2024-12-19T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/preventive-levofloxacin-found-to-reduce-drug-resistant-tb-in-household-contacts-cidrap 2024-12-19T22:51:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preventive-levofloxacin-found-to-reduce-drug-resistant-tb-in-household-contacts-cidrap 2024-12-19T22:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-completes-subject-dosing-in-phase-iii-lgmd2e-r4-therapy-trial 2024-12-19T22:34:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-completes-subject-dosing-in-phase-iii-lgmd2e-r4-therapy-trial 2024-12-19T22:34:18+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-wins-fda-approval-for-a-rare-disease-therapy-that-lowers-triglycerides-stat-news 2024-12-19T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-wins-fda-approval-for-a-rare-disease-therapy-that-lowers-triglycerides-stat-news 2024-12-19T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/exelixis-downgraded-to-market-perform-despite-price-target-increase-to-40 2024-12-19T22:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exelixis-downgraded-to-market-perform-despite-price-target-increase-to-40 2024-12-19T22:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/pepromene-bio-secures-11-million-investment-to-advance-baff-r-car-t-cell-therapy-for-follicular-lymphoma 2024-12-19T21:54:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pepromene-bio-secures-11-million-investment-to-advance-baff-r-car-t-cell-therapy-for-follicular-lymphoma 2024-12-19T21:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/drug-farm-partners-with-nih-to-develop-treatment-for-rosah-syndrome 2024-12-19T21:43:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-farm-partners-with-nih-to-develop-treatment-for-rosah-syndrome 2024-12-19T21:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/italy-joins-the-list-of-countries-recommending-restrictions-on-puberty-blockers-for-gender 2024-12-19T21:41:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italy-joins-the-list-of-countries-recommending-restrictions-on-puberty-blockers-for-gender 2024-12-19T21:41:15+00:00 weekly 0.7 https://trial.medpath.com/news/myriad-genetics-riskscore-study-named-one-of-the-top-10 2024-12-19T21:17:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myriad-genetics-riskscore-study-named-one-of-the-top-10 2024-12-19T21:17:09+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-announces-first-patient-dosed-in-pivotal-phase-3-globenewswire 2024-12-19T21:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-announces-first-patient-dosed-in-pivotal-phase-3-globenewswire 2024-12-19T21:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/odronextamab-demonstrates-safety-in-treating-dlbcl-population-cancer-network 2024-12-19T21:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/odronextamab-demonstrates-safety-in-treating-dlbcl-population-cancer-network 2024-12-19T21:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/parents-can-reliably-report-their-child-s-eoe-symptoms-over-time-research-horizons 2024-12-19T20:36:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parents-can-reliably-report-their-child-s-eoe-symptoms-over-time-research-horizons 2024-12-19T20:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/newest-chikungunya-vaccine-candidate-s-benefits-are-measurable-vax-before-travel 2024-12-19T20:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newest-chikungunya-vaccine-candidate-s-benefits-are-measurable-vax-before-travel 2024-12-19T20:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/patients-with-disability-facing-barriers-to-access-clinical-trials-for-new-drugs-and-treatments 2024-12-19T20:29:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patients-with-disability-facing-barriers-to-access-clinical-trials-for-new-drugs-and-treatments 2024-12-19T20:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/federal-jury-awards-lindis-biotech-50-million-in-patent-infringement-case-against-amgen-s-blincyto 2024-12-19T20:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/federal-jury-awards-lindis-biotech-50-million-in-patent-infringement-case-against-amgen-s-blincyto 2024-12-19T20:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2024-12-19T19:59:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-issues-complete-response-globenewswire 2024-12-19T19:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/lexaria-s-registered-glp-1-study-4-begins-dosing-stock-titan 2024-12-19T19:51:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexaria-s-registered-glp-1-study-4-begins-dosing-stock-titan 2024-12-19T19:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/nab-paclitaxel-combo-improves-response-vs-soc-in-her2-breast-cancer 2024-12-19T19:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nab-paclitaxel-combo-improves-response-vs-soc-in-her2-breast-cancer 2024-12-19T19:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2 2024-12-19T18:51:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-announces-positive-phase-iib-breakout-study-results-in-patients-with-type-2 2024-12-19T18:51:37+00:00 weekly 0.7 https://trial.medpath.com/news/apac-leading-in-parkinson-s-disease-clinical-trials-yahoo-finance 2024-12-19T18:40:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apac-leading-in-parkinson-s-disease-clinical-trials-yahoo-finance 2024-12-19T18:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-swift-trials-show-ultra-long-acting-biologic-depemokimab-reduces-severe 2024-12-19T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-swift-trials-show-ultra-long-acting-biologic-depemokimab-reduces-severe 2024-12-19T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/targed-doses-first-participant-in-phase-1-clinical-trial-of-groundbreaking-thrombolytic 2024-12-19T17:27:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targed-doses-first-participant-in-phase-1-clinical-trial-of-groundbreaking-thrombolytic 2024-12-19T17:27:49+00:00 weekly 0.7 https://trial.medpath.com/news/review-clinical-trials-demonstrate-effectiveness-of-cannabinoids-for-managing-peripheral 2024-12-19T17:23:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-clinical-trials-demonstrate-effectiveness-of-cannabinoids-for-managing-peripheral 2024-12-19T17:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/uc-davis-health-premieres-new-documentary-on-duchenne-muscular-dystrophy-treatment 2024-12-19T17:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uc-davis-health-premieres-new-documentary-on-duchenne-muscular-dystrophy-treatment 2024-12-19T17:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/wayne-state-university-enrolls-first-michigan-patient-in-clinical-trial-of-procedure-that-may 2024-12-19T16:35:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wayne-state-university-enrolls-first-michigan-patient-in-clinical-trial-of-procedure-that-may 2024-12-19T16:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/rationale-and-design-of-a-large-trial-of-perioperative-ketamine-for-prevention-of-chronic-post 2024-12-19T16:34:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rationale-and-design-of-a-large-trial-of-perioperative-ketamine-for-prevention-of-chronic-post 2024-12-19T16:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/astria-therapeutics-expands-stock-incentive-plan-to-attract-top-talent 2024-12-19T16:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astria-therapeutics-expands-stock-incentive-plan-to-attract-top-talent 2024-12-19T16:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-expert-insights-more-options-than-ever-dermatology-times 2024-12-19T16:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-expert-insights-more-options-than-ever-dermatology-times 2024-12-19T16:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/tiximed-announces-a-2-65m-program-related-investment-from-the-helmsley-charitable 2024-12-19T16:06:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiximed-announces-a-2-65m-program-related-investment-from-the-helmsley-charitable 2024-12-19T16:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/decades-of-work-leads-to-clinical-trial-for-early-alzheimer-s-treatment-newsroom 2024-12-19T16:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/decades-of-work-leads-to-clinical-trial-for-early-alzheimer-s-treatment-newsroom 2024-12-19T16:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-inc-under-investigation-for-securities-fraud 2024-12-19T15:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-inc-under-investigation-for-securities-fraud 2024-12-19T15:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-treatments-for-chronic-hand-eczema-show-promise-in-closing-treatment-gap 2024-12-19T15:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-treatments-for-chronic-hand-eczema-show-promise-in-closing-treatment-gap 2024-12-19T15:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/alpelisib-plus-fulvestrant-in-pik3ca-mutated-hormone-receptor-positive-her2-negative 2024-12-19T15:27:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpelisib-plus-fulvestrant-in-pik3ca-mutated-hormone-receptor-positive-her2-negative 2024-12-19T15:27:06+00:00 weekly 0.7 https://trial.medpath.com/news/immunocore-doses-first-subject-in-gastrointestinal-cancer-therapy-trial 2024-12-19T15:14:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunocore-doses-first-subject-in-gastrointestinal-cancer-therapy-trial 2024-12-19T15:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/hope-biosciences-research-foundation-authorized-to-begin-phase-ii-clinical-trial-in-stem 2024-12-19T15:07:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-biosciences-research-foundation-authorized-to-begin-phase-ii-clinical-trial-in-stem 2024-12-19T15:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-phase-1-2-trial-of-gene-editing-therapy-for-primary-hyperoxaluria-1 2024-12-19T14:57:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-greenlights-phase-1-2-trial-of-gene-editing-therapy-for-primary-hyperoxaluria-1 2024-12-19T14:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/biogencell-receives-fda-fast-track-designation-with-expanded-access-for-bgc101 2024-12-19T14:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogencell-receives-fda-fast-track-designation-with-expanded-access-for-bgc101 2024-12-19T14:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/opus-genetics-receives-fda-agreement-under-special-protocol-assessment-for-phase-3 2024-12-19T14:50:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opus-genetics-receives-fda-agreement-under-special-protocol-assessment-for-phase-3 2024-12-19T14:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/omeros-narsoplimab-shows-breakthrough-3-fold-mortality-reduction-in-pivotal-ta-tma-trial 2024-12-19T14:33:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omeros-narsoplimab-shows-breakthrough-3-fold-mortality-reduction-in-pivotal-ta-tma-trial 2024-12-19T14:33:04+00:00 weekly 0.7 https://trial.medpath.com/news/could-the-tb-vaccine-in-phase-3-trials-in-malawi-be-a-game-changer 2024-12-19T14:28:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-the-tb-vaccine-in-phase-3-trials-in-malawi-be-a-game-changer 2024-12-19T14:28:24+00:00 weekly 0.7 https://trial.medpath.com/news/envoy-medical-names-seven-investigational-sites-for-participation-in-its-pivotal-clinical-study 2024-12-19T14:19:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envoy-medical-names-seven-investigational-sites-for-participation-in-its-pivotal-clinical-study 2024-12-19T14:19:15+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-submits-biologics-license-application-to-the-u-s-fda-for-ux111-aav-gene-biospace 2024-12-19T14:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-submits-biologics-license-application-to-the-u-s-fda-for-ux111-aav-gene-biospace 2024-12-19T14:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/study-validates-long-term-efficacy-of-micropulse-tlt-for-glaucoma-management 2024-12-19T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-validates-long-term-efficacy-of-micropulse-tlt-for-glaucoma-management 2024-12-19T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/pluri-congratulates-mesoblast-on-fda-approval-of-first-globenewswire 2024-12-19T13:23:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pluri-congratulates-mesoblast-on-fda-approval-of-first-globenewswire 2024-12-19T13:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-seeks-fda-approval-for-groundbreaking-friedreich-ataxia-treatment-in-children 2024-12-19T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-seeks-fda-approval-for-groundbreaking-friedreich-ataxia-treatment-in-children 2024-12-19T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/nls-pharmaceutics-and-kadimastem-announce-the-submission-of-a-request-by-morningstar 2024-12-19T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nls-pharmaceutics-and-kadimastem-announce-the-submission-of-a-request-by-morningstar 2024-12-19T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/mainz-biomed-forms-agreement-with-quest-diagnostics-to-provide-clinical-trials 2024-12-19T13:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mainz-biomed-forms-agreement-with-quest-diagnostics-to-provide-clinical-trials 2024-12-19T13:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/alumis-announces-positive-phase-1-data-for-cns-penetrant-tyk2-inhibitor-a-005 2024-12-19T13:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alumis-announces-positive-phase-1-data-for-cns-penetrant-tyk2-inhibitor-a-005 2024-12-19T13:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/scottish-patient-pioneers-new-cancer-treatment-in-europe 2024-12-19T12:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scottish-patient-pioneers-new-cancer-treatment-in-europe 2024-12-19T12:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/prothena-s-parkinson-s-study-fails-primary-endpoint-despite-some-success 2024-12-19T12:25:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prothena-s-parkinson-s-study-fails-primary-endpoint-despite-some-success 2024-12-19T12:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-to-be-added-to-the-nasdaq-biotechnology-index-company-announcement-markets-data 2024-12-19T12:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-to-be-added-to-the-nasdaq-biotechnology-index-company-announcement-markets-data 2024-12-19T12:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/mesoblast-shares-soar-on-fda-approval-for-ryoncil-therapy-capital-brief 2024-12-19T12:09:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesoblast-shares-soar-on-fda-approval-for-ryoncil-therapy-capital-brief 2024-12-19T12:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-novel-blood-clot-prevention-drugs-show-breakthrough-results-in-phase-2-trial 2024-12-19T12:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-novel-blood-clot-prevention-drugs-show-breakthrough-results-in-phase-2-trial 2024-12-19T12:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-sinks-with-placebo-showing-similar-results-to-pain-drug-bnn-bloomberg 2024-12-19T12:06:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-sinks-with-placebo-showing-similar-results-to-pain-drug-bnn-bloomberg 2024-12-19T12:06:35+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational 2024-12-19T11:49:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational 2024-12-19T11:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/remedy-plan-commences-dosing-in-phase-i-cancer-therapy-trial-clinical-trials-arena 2024-12-19T11:44:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remedy-plan-commences-dosing-in-phase-i-cancer-therapy-trial-clinical-trials-arena 2024-12-19T11:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/rheacell-receives-ema-approval-for-allo-apz2-cvu-phase-3-trial-in-chronic-venous-ulcers 2024-12-19T10:59:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rheacell-receives-ema-approval-for-allo-apz2-cvu-phase-3-trial-in-chronic-venous-ulcers 2024-12-19T10:59:59+00:00 weekly 0.7 https://trial.medpath.com/news/iarc-project-among-nature-medicine-list-of-clinical-trials-to-shape-medicine-in-2025 2024-12-19T10:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iarc-project-among-nature-medicine-list-of-clinical-trials-to-shape-medicine-in-2025 2024-12-19T10:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/omeros-corporation-s-narsoplimab-meets-primary-endpoint-in-pivotal-trial-for-stem-cell-transplant-patients 2024-12-19T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omeros-corporation-s-narsoplimab-meets-primary-endpoint-in-pivotal-trial-for-stem-cell-transplant-patients 2024-12-19T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/coherus-to-present-final-phase-2-data-on-casdozokitug-in-liver-cancer-next-month 2024-12-19T10:06:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/coherus-to-present-final-phase-2-data-on-casdozokitug-in-liver-cancer-next-month 2024-12-19T10:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/canadian-survey-reveals-care-disparities-in-mds-aml-treatment-for-elderly-patients 2024-12-19T09:29:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canadian-survey-reveals-care-disparities-in-mds-aml-treatment-for-elderly-patients 2024-12-19T09:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/results-from-the-first-cardiac-lead-post-approval-study-using-real-wor-por 2024-12-19T08:29:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-from-the-first-cardiac-lead-post-approval-study-using-real-wor-por 2024-12-19T08:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/precision-neuroscience-secures-102m-series-c-for-non-invasive-brain-computer-interface-development 2024-12-19T07:48:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-neuroscience-secures-102m-series-c-for-non-invasive-brain-computer-interface-development 2024-12-19T07:48:58+00:00 weekly 0.7 https://trial.medpath.com/news/bioxodes-meets-enrollment-milestone-in-phase-2a-intracerebral-hemorrhagic-stroke-trial 2024-12-19T07:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioxodes-meets-enrollment-milestone-in-phase-2a-intracerebral-hemorrhagic-stroke-trial 2024-12-19T07:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/rna-therapy-market-set-to-reach-4-16-billion-by-2034-as-clinical-trials-accelerate 2024-12-19T07:12:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rna-therapy-market-set-to-reach-4-16-billion-by-2034-as-clinical-trials-accelerate 2024-12-19T07:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/6-revolutionary-tech-developments-that-defined-2024 2024-12-19T06:39:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/6-revolutionary-tech-developments-that-defined-2024 2024-12-19T06:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/ildong-pharmaceutical-announced-on-the-19th-that-it-will-seek-to-re-apply-after-strengthening-clinic 2024-12-19T06:18:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ildong-pharmaceutical-announced-on-the-19th-that-it-will-seek-to-re-apply-after-strengthening-clinic 2024-12-19T06:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/oruka-therapeutics-initiates-dosing-in-phase-1-trial-for-orka-001 2024-12-19T06:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oruka-therapeutics-initiates-dosing-in-phase-1-trial-for-orka-001 2024-12-19T06:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/holoclara-initiates-phase-1-clinical-trial-evaluating-worm-derived-therapeutic-hc002-in 2024-12-19T06:12:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/holoclara-initiates-phase-1-clinical-trial-evaluating-worm-derived-therapeutic-hc002-in 2024-12-19T06:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/standard-belzutifan-dose-equally-effective-as-higher-dose-in-ccrcc-targeted-oncology 2024-12-19T06:08:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/standard-belzutifan-dose-equally-effective-as-higher-dose-in-ccrcc-targeted-oncology 2024-12-19T06:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/cognition-therapeutics-price-target-increased-by-h-c-wainwright 2024-12-19T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cognition-therapeutics-price-target-increased-by-h-c-wainwright 2024-12-19T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/marker-therapeutics-reports-positive-clinical-outcomes-for-mt-601-in-lymphoma-patients 2024-12-19T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marker-therapeutics-reports-positive-clinical-outcomes-for-mt-601-in-lymphoma-patients 2024-12-19T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-to-close-morphosys-sites-cut-330-jobs-amid-pelabresib-development-challenges 2024-12-19T04:12:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-to-close-morphosys-sites-cut-330-jobs-amid-pelabresib-development-challenges 2024-12-19T04:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-job-market-shows-signs-of-recovery-despite-continued-layoffs-in-2024 2024-12-19T04:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-job-market-shows-signs-of-recovery-despite-continued-layoffs-in-2024 2024-12-19T04:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/ira-impact-cdmos-adapt-to-navigate-small-molecule-drug-development-challenges 2024-12-19T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ira-impact-cdmos-adapt-to-navigate-small-molecule-drug-development-challenges 2024-12-19T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-mar-sa-achieves-recruitment-milestone-in-phase-iii-cancer-trial 2024-12-19T02:28:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-mar-sa-achieves-recruitment-milestone-in-phase-iii-cancer-trial 2024-12-19T02:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/open-philanthropy-backs-the-search-for-new-cures-through-old-treatments 2024-12-19T00:48:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/open-philanthropy-backs-the-search-for-new-cures-through-old-treatments 2024-12-19T00:48:52+00:00 weekly 0.7 https://trial.medpath.com/news/starpharma-receives-positive-feedback-from-fda-on-dep-r-sn38-clinical-pathway-for 2024-12-19T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/starpharma-receives-positive-feedback-from-fda-on-dep-r-sn38-clinical-pathway-for 2024-12-19T00:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-shows-rsv-vaccine-s-effectiveness-in-older-adults 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-shows-rsv-vaccine-s-effectiveness-in-older-adults 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/assembly-biosciences-secures-30-1-million-investment-from-gilead-to-boost-clinical-development 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assembly-biosciences-secures-30-1-million-investment-from-gilead-to-boost-clinical-development 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cannabidiol-linked-to-better-social-executive-function-in-tuberous-sclerosis-complex 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cannabidiol-linked-to-better-social-executive-function-in-tuberous-sclerosis-complex 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-faces-challenges-with-clinical-hold-on-diabetes-drug 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-faces-challenges-with-clinical-hold-on-diabetes-drug 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/polyrizon-strengthens-leadership-with-appointment-of-dr-michal-meir-as-senior-director-of-regulatory-and-clinical-affairs 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polyrizon-strengthens-leadership-with-appointment-of-dr-michal-meir-as-senior-director-of-regulatory-and-clinical-affairs 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-pd-l1-immunohistochemistry-and-digital-pathology 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-pd-l1-immunohistochemistry-and-digital-pathology 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-ends-clinical-trial-in-australia-and-europe 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/percheron-therapeutics-ends-clinical-trial-in-australia-and-europe 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sapience-therapeutics-receives-fda-orphan-drug 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sapience-therapeutics-receives-fda-orphan-drug 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-expands-chikungunya-vaccine-access-in-asia-through-collaboration-with-serum-institute-of-india 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-expands-chikungunya-vaccine-access-in-asia-through-collaboration-with-serum-institute-of-india 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-source-unveils-breakthrough-in-off-the-shelf-car-t-cell-therapy-at-ash-meeting 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-source-unveils-breakthrough-in-off-the-shelf-car-t-cell-therapy-at-ash-meeting 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tnf-pharmaceuticals-announces-trial-to-explore-effects-of-lead-candidate-in-sarcopenia-frailty-induced-by-glp-1-weight-loss-drugs 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tnf-pharmaceuticals-announces-trial-to-explore-effects-of-lead-candidate-in-sarcopenia-frailty-induced-by-glp-1-weight-loss-drugs 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/all-11-sectors-sell-off-but-mesoblast-jumps-52pc-on-fda-nod 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-11-sectors-sell-off-but-mesoblast-jumps-52pc-on-fda-nod 2024-12-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heartbeam-announces-us-fda-clearance-for-at-home-high-fidelity-heart-monitoring-technology 2024-12-18T23:04:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heartbeam-announces-us-fda-clearance-for-at-home-high-fidelity-heart-monitoring-technology 2024-12-18T23:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-of-risk-enabled-therapy-after-neoadjuvant-chemotherapy-for-muscle 2024-12-18T22:37:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-of-risk-enabled-therapy-after-neoadjuvant-chemotherapy-for-muscle 2024-12-18T22:37:04+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-announces-asc47-a-muscle-preserving-weight-loss-drug-candidate-for-pr-newswire 2024-12-18T22:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-announces-asc47-a-muscle-preserving-weight-loss-drug-candidate-for-pr-newswire 2024-12-18T22:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-molecular-imaging-agent-can-accurately-identify-crucial-cancer-biomarker 2024-12-18T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-molecular-imaging-agent-can-accurately-identify-crucial-cancer-biomarker 2024-12-18T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/io-trials-change-practice-in-localized-and-metastatic-bladder-cancer-targeted-oncology 2024-12-18T22:04:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-trials-change-practice-in-localized-and-metastatic-bladder-cancer-targeted-oncology 2024-12-18T22:04:38+00:00 weekly 0.7 https://trial.medpath.com/news/sabcs-2024-breast-cancer-trial-updates-and-highlights 2024-12-18T21:55:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sabcs-2024-breast-cancer-trial-updates-and-highlights 2024-12-18T21:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/health-data-works-receives-fda-breakthrough-device-designation-for-access-trackertm 2024-12-18T21:44:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-data-works-receives-fda-breakthrough-device-designation-for-access-trackertm 2024-12-18T21:44:19+00:00 weekly 0.7 https://trial.medpath.com/news/savara-s-molbreevi-advances-toward-first-ever-apap-treatment-with-fda-rolling-bla 2024-12-18T21:16:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-s-molbreevi-advances-toward-first-ever-apap-treatment-with-fda-rolling-bla 2024-12-18T21:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-greenlights-expansion-of-bivacor-artificial-heart-study-massdevice 2024-12-18T21:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-greenlights-expansion-of-bivacor-artificial-heart-study-massdevice 2024-12-18T21:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/recent-sec-case-against-biotech-company-highlights-the-intersection-between-fda 2024-12-18T20:32:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-sec-case-against-biotech-company-highlights-the-intersection-between-fda 2024-12-18T20:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/c4-therapeutics-stock-hits-52-week-low-amid-market-volatility 2024-12-18T20:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/c4-therapeutics-stock-hits-52-week-low-amid-market-volatility 2024-12-18T20:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/framework-amending-the-uk-clinical-trial-regulations-laid-before-parliament-jd-supra 2024-12-18T19:14:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/framework-amending-the-uk-clinical-trial-regulations-laid-before-parliament-jd-supra 2024-12-18T19:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-findings-shaping-the-future-of-breast-cancer-care-from-sabcs-2024 2024-12-18T19:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-findings-shaping-the-future-of-breast-cancer-care-from-sabcs-2024 2024-12-18T19:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/consolidation-durvalumab-improves-pfs-in-unresectable-stage-iii-nsclc-without 2024-12-18T19:07:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consolidation-durvalumab-improves-pfs-in-unresectable-stage-iii-nsclc-without 2024-12-18T19:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/cymbalta-bottles-recalled-1-in-3-older-adults-are-lonely-walking-off-depression 2024-12-18T18:29:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cymbalta-bottles-recalled-1-in-3-older-adults-are-lonely-walking-off-depression 2024-12-18T18:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-oncology-provides-a-clinical-update-for-ramp-203-trial-in-advanced-kras-biospace 2024-12-18T18:23:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-oncology-provides-a-clinical-update-for-ramp-203-trial-in-advanced-kras-biospace 2024-12-18T18:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-life-sciences-announces-first-patient-with-moderate-alzheimer-s-disease-dosed 2024-12-18T18:23:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiziana-life-sciences-announces-first-patient-with-moderate-alzheimer-s-disease-dosed 2024-12-18T18:23:12+00:00 weekly 0.7 https://trial.medpath.com/news/vandria-announces-first-subjects-dosed-in-its-first-in-human-phase-1-clinical-trial-of-vna-318 2024-12-18T18:23:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vandria-announces-first-subjects-dosed-in-its-first-in-human-phase-1-clinical-trial-of-vna-318 2024-12-18T18:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-evaluate-minimally-invasive-procedure-for-women-with-pelvic-venous-disease 2024-12-18T17:37:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-evaluate-minimally-invasive-procedure-for-women-with-pelvic-venous-disease 2024-12-18T17:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/breckenridge-announces-final-fda-approval-for-methadone-hydrochloride-multi-dose-injection 2024-12-18T17:33:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breckenridge-announces-final-fda-approval-for-methadone-hydrochloride-multi-dose-injection 2024-12-18T17:33:46+00:00 weekly 0.7 https://trial.medpath.com/news/karmanos-cancer-institute-physicians-begin-prescribing-new-fda-approved-pr-newswire 2024-12-18T17:29:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karmanos-cancer-institute-physicians-begin-prescribing-new-fda-approved-pr-newswire 2024-12-18T17:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/ose-immunotherapeutics-to-present-anti-il-7r-lusvertikimab-globenewswire 2024-12-18T17:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ose-immunotherapeutics-to-present-anti-il-7r-lusvertikimab-globenewswire 2024-12-18T17:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/mount-sinai-study-reveals-immune-modulatory-mechanism-of-lurbinectedin-in-small-cell 2024-12-18T16:40:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mount-sinai-study-reveals-immune-modulatory-mechanism-of-lurbinectedin-in-small-cell 2024-12-18T16:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/perceived-barriers-and-facilitators-of-staff-recruiting-participants-to-a-randomised-controlled-trials 2024-12-18T16:36:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perceived-barriers-and-facilitators-of-staff-recruiting-participants-to-a-randomised-controlled-trials 2024-12-18T16:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/limitation-of-site-stratified-cox-regression-analysis-in-survival-data-trials-biomed-central 2024-12-18T16:35:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/limitation-of-site-stratified-cox-regression-analysis-in-survival-data-trials-biomed-central 2024-12-18T16:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/primary-lung-tumor-sbrt-followed-by-concurrent-mediastinal-chemoradiotherapy-and 2024-12-18T16:00:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-lung-tumor-sbrt-followed-by-concurrent-mediastinal-chemoradiotherapy-and 2024-12-18T16:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-emerges-as-promising-treatment-for-systemic-lupus-erythematosus 2024-12-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-emerges-as-promising-treatment-for-systemic-lupus-erythematosus 2024-12-18T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-veterinary-authorities-confirm-histamine-contamination-in-equine-antibiotic-batches-following-adverse-event-investigation 2024-12-18T15:44:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-veterinary-authorities-confirm-histamine-contamination-in-equine-antibiotic-batches-following-adverse-event-investigation 2024-12-18T15:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/omacetaxine-plus-azacitidine-for-excess-blasts-mds-safety-long-term-outcomes-favorable 2024-12-18T15:34:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omacetaxine-plus-azacitidine-for-excess-blasts-mds-safety-long-term-outcomes-favorable 2024-12-18T15:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/east-texas-doctor-gets-fda-approval-for-new-back-pain-procedure-cbs19-tv 2024-12-18T15:19:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/east-texas-doctor-gets-fda-approval-for-new-back-pain-procedure-cbs19-tv 2024-12-18T15:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/arthrosi-therapeutics-surpasses-50-patient-enrollment-in-pivotal-phase-3-reduce-2 2024-12-18T14:33:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arthrosi-therapeutics-surpasses-50-patient-enrollment-in-pivotal-phase-3-reduce-2 2024-12-18T14:33:22+00:00 weekly 0.7 https://trial.medpath.com/news/metavia-announces-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241 2024-12-18T14:28:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metavia-announces-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241 2024-12-18T14:28:20+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-car-e-therapy-extends-cancer-free-period-for-patients 2024-12-18T14:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-car-e-therapy-extends-cancer-free-period-for-patients 2024-12-18T14:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/tenya-therapeutics-sees-mixed-success-in-hcm-gene-therapy-trial-clinical-trials-arena 2024-12-18T14:16:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenya-therapeutics-sees-mixed-success-in-hcm-gene-therapy-trial-clinical-trials-arena 2024-12-18T14:16:24+00:00 weekly 0.7 https://trial.medpath.com/news/coya-therapeutics-provides-enrollment-update-of-the-investigator-initiated-phase-1-study-of 2024-12-18T14:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/coya-therapeutics-provides-enrollment-update-of-the-investigator-initiated-phase-1-study-of 2024-12-18T14:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-breast-cancer-surgery-offer-patients-improved-surgical-outcomes 2024-12-18T14:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-breast-cancer-surgery-offer-patients-improved-surgical-outcomes 2024-12-18T14:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/monogram-technologies-provides-510-k-submission-update-following-positive-meeting-with-fda 2024-12-18T13:38:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monogram-technologies-provides-510-k-submission-update-following-positive-meeting-with-fda 2024-12-18T13:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/contemporary-pediatrics-top-3-fda-approvals-of-2024 2024-12-18T13:13:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contemporary-pediatrics-top-3-fda-approvals-of-2024 2024-12-18T13:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-veozah-first-hormone-free-hot-flash-drug-issued-black-box-warning 2024-12-18T13:12:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-veozah-first-hormone-free-hot-flash-drug-issued-black-box-warning 2024-12-18T13:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-announces-rare-pediatric-disease-globenewswire 2024-12-18T13:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-precision-medicines-announces-rare-pediatric-disease-globenewswire 2024-12-18T13:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/acalabrutinib-regimen-demonstrates-efficacy-in-de-novo-mantle-cell-lymphoma-onclive 2024-12-18T13:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acalabrutinib-regimen-demonstrates-efficacy-in-de-novo-mantle-cell-lymphoma-onclive 2024-12-18T13:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/zyversa-to-showcase-breakthrough-kidney-disease-drug-at-jpm-healthcare-conference-2025 2024-12-18T12:57:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zyversa-to-showcase-breakthrough-kidney-disease-drug-at-jpm-healthcare-conference-2025 2024-12-18T12:57:05+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-gecacitinib-vs-hydroxyurea-in-patients-with-intermediate-2-or-high-risk-myelofibrosis 2024-12-18T12:37:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-gecacitinib-vs-hydroxyurea-in-patients-with-intermediate-2-or-high-risk-myelofibrosis 2024-12-18T12:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/neurizon-files-ind-application-to-support-healey-als-platform-trial-yahoo-finance 2024-12-18T12:25:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurizon-files-ind-application-to-support-healey-als-platform-trial-yahoo-finance 2024-12-18T12:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-seeks-accelerated-fda-approval-for-brain-tumor-treatment 2024-12-18T12:22:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-seeks-accelerated-fda-approval-for-brain-tumor-treatment 2024-12-18T12:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/controversial-covid-study-that-promoted-unproven-treatment-retracted-after-four-year-saga 2024-12-18T12:20:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/controversial-covid-study-that-promoted-unproven-treatment-retracted-after-four-year-saga 2024-12-18T12:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-vivo-gene-editing-trial-for-hepatitis-b-approved-in-hong-kong-dtil-stock-news 2024-12-18T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-vivo-gene-editing-trial-for-hepatitis-b-approved-in-hong-kong-dtil-stock-news 2024-12-18T12:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/aurion-biotech-announces-topline-results-from-phase-1-2-trial-of-aurn001-for-corneal-edema 2024-12-18T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurion-biotech-announces-topline-results-from-phase-1-2-trial-of-aurn001-for-corneal-edema 2024-12-18T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/viatris-announces-publication-of-phase-2b-care-study-data-for-cenerimod-in-lancet-rheumatology 2024-12-18T12:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viatris-announces-publication-of-phase-2b-care-study-data-for-cenerimod-in-lancet-rheumatology 2024-12-18T12:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/positive-results-advance-peanut-tablet-to-phase-ii-development-globenewswire 2024-12-18T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-results-advance-peanut-tablet-to-phase-ii-development-globenewswire 2024-12-18T12:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/fred-hutchinson-biostatistician-pioneers-novel-approaches-in-cancer-clinical-trial-design 2024-12-18T12:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fred-hutchinson-biostatistician-pioneers-novel-approaches-in-cancer-clinical-trial-design 2024-12-18T12:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-s-novel-glp-1-drug-gets-fda-green-light-for-head-to-head-trial-against-eli 2024-12-18T11:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-s-novel-glp-1-drug-gets-fda-green-light-for-head-to-head-trial-against-eli 2024-12-18T11:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-s-manufacturing-push-and-other-2024-trends-biospace-iheart 2024-12-18T11:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-s-manufacturing-push-and-other-2024-trends-biospace-iheart 2024-12-18T11:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/further-research-on-balloon-guide-catheters-required-following-inconclusive-protect-mt-results 2024-12-18T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/further-research-on-balloon-guide-catheters-required-following-inconclusive-protect-mt-results 2024-12-18T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-submits-application-to-the-european-medicines-agency-seeking-biospace 2024-12-18T10:53:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-submits-application-to-the-european-medicines-agency-seeking-biospace 2024-12-18T10:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/patient-navigation-services-evolve-in-oncology-care-new-cms-codes-and-implementation-challenges-discussed-at-pcoc-2024 2024-12-18T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-navigation-services-evolve-in-oncology-care-new-cms-codes-and-implementation-challenges-discussed-at-pcoc-2024 2024-12-18T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/egyptian-drug-authority-approves-lilly-and-eva-s-insulin-injection-yahoo-finance 2024-12-18T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/egyptian-drug-authority-approves-lilly-and-eva-s-insulin-injection-yahoo-finance 2024-12-18T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-reports-progress-in-cancer-care-access-despite-ongoing-drug-shortage-challenges 2024-12-18T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-reports-progress-in-cancer-care-access-despite-ongoing-drug-shortage-challenges 2024-12-18T08:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/financial-toxicity-remains-major-barrier-in-cancer-care-despite-improved-patient-experience 2024-12-18T08:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/financial-toxicity-remains-major-barrier-in-cancer-care-despite-improved-patient-experience 2024-12-18T08:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-clinical-pathways-need-rapid-updates-to-keep-pace-with-treatment-innovation 2024-12-18T08:18:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncology-clinical-pathways-need-rapid-updates-to-keep-pace-with-treatment-innovation 2024-12-18T08:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/applied-dna-customer-uhkt-initiates-phase-i-clinical-trial-of-uhkt-car123-01 2024-12-18T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-dna-customer-uhkt-initiates-phase-i-clinical-trial-of-uhkt-car123-01 2024-12-18T08:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-pharmacists-expand-clinical-roles-push-for-provider-status-recognition 2024-12-18T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncology-pharmacists-expand-clinical-roles-push-for-provider-status-recognition 2024-12-18T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-antimicrobial-technology-with-unrivalled-efficacy-poised-to-revolutionise-global 2024-12-18T08:06:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-antimicrobial-technology-with-unrivalled-efficacy-poised-to-revolutionise-global 2024-12-18T08:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/vancouver-biotech-briacell-to-raise-us-5-5-million-in-share-offering 2024-12-18T08:03:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vancouver-biotech-briacell-to-raise-us-5-5-million-in-share-offering 2024-12-18T08:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-for-invasive-fungal-infections 2024-12-18T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scynexis-initiates-dosing-in-phase-1-trial-of-scy-247-for-invasive-fungal-infections 2024-12-18T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/jenavalve-announces-first-case-in-new-heart-valve-registry-massdevice 2024-12-18T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jenavalve-announces-first-case-in-new-heart-valve-registry-massdevice 2024-12-18T07:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/thermo-fisher-scientific-and-eversana-partner-to-advance-ngs-based-precision-medicine-in-blood-cancers 2024-12-18T07:40:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thermo-fisher-scientific-and-eversana-partner-to-advance-ngs-based-precision-medicine-in-blood-cancers 2024-12-18T07:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/scipher-medicine-expands-precision-medicine-partnerships-to-transform-rheumatoid-arthritis-treatment 2024-12-18T06:37:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scipher-medicine-expands-precision-medicine-partnerships-to-transform-rheumatoid-arthritis-treatment 2024-12-18T06:37:44+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-alzheimer-s-treatment-kisunla-secures-fourth-major-market-approval-with-nmpa 2024-12-18T05:59:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-alzheimer-s-treatment-kisunla-secures-fourth-major-market-approval-with-nmpa 2024-12-18T05:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-teva-say-study-results-show-gut-disease-drug-could-be-best-in-class 2024-12-18T05:28:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-teva-say-study-results-show-gut-disease-drug-could-be-best-in-class 2024-12-18T05:28:35+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-sees-37-cut-in-risk-of-death-in-phase-ii-pancreatic-cancer-trial 2024-12-18T05:28:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-sees-37-cut-in-risk-of-death-in-phase-ii-pancreatic-cancer-trial 2024-12-18T05:28:13+00:00 weekly 0.7 https://trial.medpath.com/news/oneoncology-cmo-emphasizes-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-12-18T04:36:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oneoncology-cmo-emphasizes-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-12-18T04:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-leaders-highlight-growing-challenges-in-managing-cancer-treatment-data 2024-12-18T04:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncology-leaders-highlight-growing-challenges-in-managing-cancer-treatment-data 2024-12-18T04:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/ira-implementation-reshapes-cancer-drug-development-and-access-landscape 2024-12-18T04:29:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ira-implementation-reshapes-cancer-drug-development-and-access-landscape 2024-12-18T04:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-grants-orphan-medicinal-product-designation-to-agios-mitapivat-for-sickle-cell-disease 2024-12-18T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-grants-orphan-medicinal-product-designation-to-agios-mitapivat-for-sickle-cell-disease 2024-12-18T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-enters-obesity-market-with-112m-deal-for-hansoh-s-oral-glp-1-drug 2024-12-18T03:59:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-enters-obesity-market-with-112m-deal-for-hansoh-s-oral-glp-1-drug 2024-12-18T03:59:34+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-evolution-in-2025-strengthening-site-patient-relationships-through-technology 2024-12-18T03:01:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-evolution-in-2025-strengthening-site-patient-relationships-through-technology 2024-12-18T03:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-inc-filed-sec-form-8-k-other-events-financial-statements-and-exhibits 2024-12-18T02:40:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipocine-inc-filed-sec-form-8-k-other-events-financial-statements-and-exhibits 2024-12-18T02:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-resistance-to-paxlovid-is-uncommon-cidrap 2024-12-18T02:31:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-resistance-to-paxlovid-is-uncommon-cidrap 2024-12-18T02:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/eyedna-therapeutics-receives-fda-rare-pediatric-disease-designation-for-hora-pde6b 2024-12-18T00:38:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyedna-therapeutics-receives-fda-rare-pediatric-disease-designation-for-hora-pde6b 2024-12-18T00:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shares-surge-following-positive-mid-stage-study-results 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-shares-surge-following-positive-mid-stage-study-results 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-gilead-s-trodelvy-for-lung-cancer-treatment 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-gilead-s-trodelvy-for-lung-cancer-treatment 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ucsf-led-study-advances-understanding-and-treatment-of-hidradenitis-suppurativa 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsf-led-study-advances-understanding-and-treatment-of-hidradenitis-suppurativa 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retina-top-items-in-ophthalmology-for-2024 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retina-top-items-in-ophthalmology-for-2024 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/noema-pharma-appoints-volker-knappertz-m-d-as-executive-vice-president-of-research-development 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noema-pharma-appoints-volker-knappertz-m-d-as-executive-vice-president-of-research-development 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/startup-siteone-secures-100m-to-forge-ahead-with-novel-non-opioid-pain-meds 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/startup-siteone-secures-100m-to-forge-ahead-with-novel-non-opioid-pain-meds 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medera-s-novoheart-partners-with-curi-bio-to-revolutionize-human-based-cardiac-drug-screening 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medera-s-novoheart-partners-with-curi-bio-to-revolutionize-human-based-cardiac-drug-screening 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-to-present-new-data-at-2025-asco-gi-symposium-and-host-r-d-update-day 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-tau-to-present-new-data-at-2025-asco-gi-symposium-and-host-r-d-update-day 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-to-present-non-clinical-data-on-al001-at-society-of-toxicology-2025 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-to-present-non-clinical-data-on-al001-at-society-of-toxicology-2025 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-reports-resuls-from-phase-iib-study-of-avicursen 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/percheron-therapeutics-reports-resuls-from-phase-iib-study-of-avicursen 2024-12-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teva-and-sanofi-jump-on-experimental-bowel-disease-drug-success-yahoo-finance 2024-12-17T21:49:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-and-sanofi-jump-on-experimental-bowel-disease-drug-success-yahoo-finance 2024-12-17T21:49:01+00:00 weekly 0.7 https://trial.medpath.com/news/research-spotlight-pancreatic-cancer-a-look-back-at-2024 2024-12-17T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-spotlight-pancreatic-cancer-a-look-back-at-2024 2024-12-17T21:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/structure-therapeutics-unveils-breakthrough-oral-obesity-drug-first-in-class-amylin 2024-12-17T21:19:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/structure-therapeutics-unveils-breakthrough-oral-obesity-drug-first-in-class-amylin 2024-12-17T21:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/partnership-advances-targeted-therapies-for-blood-cancers-newswise 2024-12-17T20:49:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/partnership-advances-targeted-therapies-for-blood-cancers-newswise 2024-12-17T20:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/asco-reading-room-sc-vs-iv-trastuzumab-pertuzumab-a-time-and-motion-substudy-of 2024-12-17T20:21:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asco-reading-room-sc-vs-iv-trastuzumab-pertuzumab-a-time-and-motion-substudy-of 2024-12-17T20:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-idmc-recommendation-of-move-forward-dose-in-part-2a-of-pr-newswire 2024-12-17T20:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-announces-idmc-recommendation-of-move-forward-dose-in-part-2a-of-pr-newswire 2024-12-17T20:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/177lu-dotatate-is-a-viable-treatment-in-meningioma-targeted-oncology 2024-12-17T20:03:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/177lu-dotatate-is-a-viable-treatment-in-meningioma-targeted-oncology 2024-12-17T20:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonary-sarcoidosis-treatment-efzofitimod-phase-3-trial-to-go-on 2024-12-17T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonary-sarcoidosis-treatment-efzofitimod-phase-3-trial-to-go-on 2024-12-17T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/precision-treatment-for-alzheimer-s-disease-reduces-phosphorylated-tau-mdlinx 2024-12-17T19:25:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-treatment-for-alzheimer-s-disease-reduces-phosphorylated-tau-mdlinx 2024-12-17T19:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/ondine-commencing-us-phase-3-clinical-trial-webdisclosure 2024-12-17T19:15:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ondine-commencing-us-phase-3-clinical-trial-webdisclosure 2024-12-17T19:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-launches-revolutionary-morph-dna-steerable-introducer-advances-stock-titan 2024-12-17T19:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-launches-revolutionary-morph-dna-steerable-introducer-advances-stock-titan 2024-12-17T19:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/does-medical-cannabis-have-physical-mental-health-risks-rutgers-health-kicks-off-study 2024-12-17T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/does-medical-cannabis-have-physical-mental-health-risks-rutgers-health-kicks-off-study 2024-12-17T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/study-supports-role-of-ctdna-in-predicting-outcomes-in-hr-early-breast-cancer 2024-12-17T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-supports-role-of-ctdna-in-predicting-outcomes-in-hr-early-breast-cancer 2024-12-17T19:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/adrienne-waks-on-margot-tbcrc052-phase-ii-trial-in-her2-positive-breast-cancer 2024-12-17T18:55:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adrienne-waks-on-margot-tbcrc052-phase-ii-trial-in-her2-positive-breast-cancer 2024-12-17T18:55:31+00:00 weekly 0.7 https://trial.medpath.com/news/analysts-tell-moderna-investors-to-hold-after-2024-s-steep-drop-biospace 2024-12-17T17:21:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/analysts-tell-moderna-investors-to-hold-after-2024-s-steep-drop-biospace 2024-12-17T17:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/merck-targets-2025-rsv-season-with-antibody-now-under-fda-review-biopharma-dive 2024-12-17T17:15:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-targets-2025-rsv-season-with-antibody-now-under-fda-review-biopharma-dive 2024-12-17T17:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/neural-stem-cell-transplants-show-promise-for-spinal-injuries-neuroscience-news 2024-12-17T17:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neural-stem-cell-transplants-show-promise-for-spinal-injuries-neuroscience-news 2024-12-17T17:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/top-cancer-treatment-advances-at-msk-in-2024 2024-12-17T16:56:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-cancer-treatment-advances-at-msk-in-2024 2024-12-17T16:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/muscle-stem-cell-therapy-offers-hope-for-duchenne-patients-technology-networks 2024-12-17T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/muscle-stem-cell-therapy-offers-hope-for-duchenne-patients-technology-networks 2024-12-17T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-patients-interested-and-anxious-on-xenotransplantation-clinical-trials 2024-12-17T16:50:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-patients-interested-and-anxious-on-xenotransplantation-clinical-trials 2024-12-17T16:50:29+00:00 weekly 0.7 https://trial.medpath.com/news/dc-circuit-affirms-fda-s-fast-track-denial-of-vanda-stomach-drug-bloomberg-law-news 2024-12-17T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dc-circuit-affirms-fda-s-fast-track-denial-of-vanda-stomach-drug-bloomberg-law-news 2024-12-17T16:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/immune-suppressing-drug-does-not-improve-covid-19-recovery-study-vumc-news 2024-12-17T15:54:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-suppressing-drug-does-not-improve-covid-19-recovery-study-vumc-news 2024-12-17T15:54:10+00:00 weekly 0.7 https://trial.medpath.com/news/granules-pharmaceuticals-gains-u-s-fda-approval-for-lisdexamfetamine-dimesylate 2024-12-17T15:33:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/granules-pharmaceuticals-gains-u-s-fda-approval-for-lisdexamfetamine-dimesylate 2024-12-17T15:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-complete-response-letter-to-subcutaneous-amivantamab-bla-in-egfr-nsclc 2024-12-17T15:18:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-to-subcutaneous-amivantamab-bla-in-egfr-nsclc 2024-12-17T15:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-woman-living-healthy-with-kidney-sourced-from-pig 2024-12-17T15:12:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-woman-living-healthy-with-kidney-sourced-from-pig 2024-12-17T15:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/camizestrant-outperforms-fulvestrant-in-er-her2-breast-cancer 2024-12-17T15:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/camizestrant-outperforms-fulvestrant-in-er-her2-breast-cancer 2024-12-17T15:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/menin-inhibitor-clinical-trial-puts-pediatric-leukemia-patient-in-remission 2024-12-17T15:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/menin-inhibitor-clinical-trial-puts-pediatric-leukemia-patient-in-remission 2024-12-17T15:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-drug-comes-to-market-with-help-of-renowned-university-of-kansas 2024-12-17T14:49:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-drug-comes-to-market-with-help-of-renowned-university-of-kansas 2024-12-17T14:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/arcturus-shares-maintain-buy-rating-as-ema-nods-to-covid-19-vaccine-investing-com 2024-12-17T14:29:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcturus-shares-maintain-buy-rating-as-ema-nods-to-covid-19-vaccine-investing-com 2024-12-17T14:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-orphan-drug-designation-for-jaguar-health-s-crofelemer-for-treatment-of 2024-12-17T14:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-orphan-drug-designation-for-jaguar-health-s-crofelemer-for-treatment-of 2024-12-17T14:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/sonnet-biotherapeutics-holdings-inc-reports-significant-clinical-progress-and-financial-updates-for-fiscal-year-2024 2024-12-17T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonnet-biotherapeutics-holdings-inc-reports-significant-clinical-progress-and-financial-updates-for-fiscal-year-2024 2024-12-17T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-highlights-recent-progress-on-active-phase-iib-clinical-trial 2024-12-17T13:51:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-highlights-recent-progress-on-active-phase-iib-clinical-trial 2024-12-17T13:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-status-to-gilead-s-lung-cancer-drug-investing-com 2024-12-17T13:42:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-status-to-gilead-s-lung-cancer-drug-investing-com 2024-12-17T13:42:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-lipocine-for-lpcn-1148-as-a-treatment-for-pr-newswire 2024-12-17T13:32:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-lipocine-for-lpcn-1148-as-a-treatment-for-pr-newswire 2024-12-17T13:32:25+00:00 weekly 0.7 https://trial.medpath.com/news/indapta-therapeutics-secures-22-5-million-to-advance-clinical-trials-of-innovative-cancer 2024-12-17T13:22:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indapta-therapeutics-secures-22-5-million-to-advance-clinical-trials-of-innovative-cancer 2024-12-17T13:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-s-diabetes-drug-shows-breakthrough-results-in-phase-ii-trial-stock-titan 2024-12-17T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-s-diabetes-drug-shows-breakthrough-results-in-phase-ii-trial-stock-titan 2024-12-17T13:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-announces-first-in-world-leadless-pacing-procedures-in-the-left-bundle-branch 2024-12-17T13:09:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-announces-first-in-world-leadless-pacing-procedures-in-the-left-bundle-branch 2024-12-17T13:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/mediwound-to-host-virtual-key-opinion-leader-event-to-globenewswire 2024-12-17T13:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mediwound-to-host-virtual-key-opinion-leader-event-to-globenewswire 2024-12-17T13:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/glyconex-announces-first-patient-dosed-in-phase-3-clinical-trial-for-denosumab-biosimilar 2024-12-17T12:53:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glyconex-announces-first-patient-dosed-in-phase-3-clinical-trial-for-denosumab-biosimilar 2024-12-17T12:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-fda-bid-for-subcutaneous-rybrevant-falls-short-biospace 2024-12-17T12:31:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-fda-bid-for-subcutaneous-rybrevant-falls-short-biospace 2024-12-17T12:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/eylea-hd-r-aflibercept-injection-8-mg-phase-3-trial-meets-globenewswire 2024-12-17T12:23:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eylea-hd-r-aflibercept-injection-8-mg-phase-3-trial-meets-globenewswire 2024-12-17T12:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/teen-substance-use-hits-historic-lows-mtf-survey-shows-continued-post-pandemic-decline 2024-12-17T12:19:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teen-substance-use-hits-historic-lows-mtf-survey-shows-continued-post-pandemic-decline 2024-12-17T12:19:10+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-halts-key-cancer-drug-trials-initiates-strategic-review-amid-clinical-setback 2024-12-17T12:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-halts-key-cancer-drug-trials-initiates-strategic-review-amid-clinical-setback 2024-12-17T12:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/icymi-highlights-from-ims-2024-american-journal-of-managed-care 2024-12-17T12:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icymi-highlights-from-ims-2024-american-journal-of-managed-care 2024-12-17T12:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-biospace 2024-12-17T11:23:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highfield-biopharmaceuticals-granted-clearance-of-ind-in-china-for-clinical-trial-of-its-biospace 2024-12-17T11:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-ltd-s-strategic-advancements-and-pipeline-strengthen-buy-rating 2024-12-17T11:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-ltd-s-strategic-advancements-and-pipeline-strengthen-buy-rating 2024-12-17T11:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-driving-biomea-fusion-stock-soars-25-markets-insider 2024-12-17T10:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-driving-biomea-fusion-stock-soars-25-markets-insider 2024-12-17T10:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/ou-health-sciences-leads-clinical-trial-of-device-designed-to-induce-ovulation-in-women-with-pcos 2024-12-17T10:44:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ou-health-sciences-leads-clinical-trial-of-device-designed-to-induce-ovulation-in-women-with-pcos 2024-12-17T10:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-therapeutics-cushing-s-syndrome-therapy-shows-promise-in-phase-iii-trial-yahoo 2024-12-17T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-therapeutics-cushing-s-syndrome-therapy-shows-promise-in-phase-iii-trial-yahoo 2024-12-17T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/nuclear-isotopes-emerge-as-promising-tool-in-cancer-clinical-trials-despite-production-challenges 2024-12-17T10:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuclear-isotopes-emerge-as-promising-tool-in-cancer-clinical-trials-despite-production-challenges 2024-12-17T10:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/esocap-publishes-positive-phase-ii-results-for-eso-101-in-treating-eosinophilic-esophagitis 2024-12-17T10:11:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esocap-publishes-positive-phase-ii-results-for-eso-101-in-treating-eosinophilic-esophagitis 2024-12-17T10:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/mytomorrows-enhances-clinical-trial-platform-with-isrctn-integration-and-ai-capabilities 2024-12-17T10:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mytomorrows-enhances-clinical-trial-platform-with-isrctn-integration-and-ai-capabilities 2024-12-17T10:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/quadruplet-therapy-and-mrd-monitoring-show-promise-in-newly-diagnosed-multiple-myeloma-treatment 2024-12-17T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quadruplet-therapy-and-mrd-monitoring-show-promise-in-newly-diagnosed-multiple-myeloma-treatment 2024-12-17T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exegi-pharma-reports-positive-topline-results-in-exe-346-prof-phase-1b-study 2024-12-17T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exegi-pharma-reports-positive-topline-results-in-exe-346-prof-phase-1b-study 2024-12-17T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/senders-pediatrics-seeks-young-participants-for-epstein-barr-virus-vaccine-clinical-trial 2024-12-17T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senders-pediatrics-seeks-young-participants-for-epstein-barr-virus-vaccine-clinical-trial 2024-12-17T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/butantan-institute-seeks-anvisa-approval-for-single-dose-dengue-vaccine 2024-12-17T08:47:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/butantan-institute-seeks-anvisa-approval-for-single-dose-dengue-vaccine 2024-12-17T08:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-training-tool-developed-to-enhance-biosimilar-switch-communication-between-prescribers-and-patients 2024-12-17T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-training-tool-developed-to-enhance-biosimilar-switch-communication-between-prescribers-and-patients 2024-12-17T08:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-advanced-renal-cell-carcinoma-urotoday 2024-12-17T08:20:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-advanced-renal-cell-carcinoma-urotoday 2024-12-17T08:20:08+00:00 weekly 0.7 https://trial.medpath.com/news/uncommon-cures-and-carexso-partner-to-expand-orphan-drug-clinical-trials-in-the-middle-east 2024-12-17T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uncommon-cures-and-carexso-partner-to-expand-orphan-drug-clinical-trials-in-the-middle-east 2024-12-17T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-j-j-navigated-regulatory-approval-for-a-drug-to-watch-clarivate 2024-12-17T08:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-j-j-navigated-regulatory-approval-for-a-drug-to-watch-clarivate 2024-12-17T08:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-full-approval-for-andexxa-following-dosing-uncertainties 2024-12-17T07:13:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-denies-full-approval-for-andexxa-following-dosing-uncertainties 2024-12-17T07:13:46+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-btk-degrader-shows-promise-in-clinical-trials 2024-12-17T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-btk-degrader-shows-promise-in-clinical-trials 2024-12-17T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurogene-s-gene-therapy-shows-promise-for-rett-syndrome-amid-clinical-and-market-risks 2024-12-17T04:41:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurogene-s-gene-therapy-shows-promise-for-rett-syndrome-amid-clinical-and-market-risks 2024-12-17T04:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-s-promising-growth-prospects-buy-rating-backed-by-positive-clinical-results 2024-12-17T04:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-s-promising-growth-prospects-buy-rating-backed-by-positive-clinical-results 2024-12-17T04:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/health-check-clinical-trials-don-t-sleigh-down-for-the-silly-season-stockhead 2024-12-17T01:49:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-check-clinical-trials-don-t-sleigh-down-for-the-silly-season-stockhead 2024-12-17T01:49:48+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-partners-with-serum-institute-of-india-for-global-mpox-vaccine-manufacturing 2024-12-17T01:31:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-nordic-partners-with-serum-institute-of-india-for-global-mpox-vaccine-manufacturing 2024-12-17T01:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/are-you-over-18-generally-healthy-and-assigned-male-at-birth-the-reporter-uab 2024-12-17T01:22:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-you-over-18-generally-healthy-and-assigned-male-at-birth-the-reporter-uab 2024-12-17T01:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/large-clinical-study-finds-home-based-virtual-reality-device-creates-greater-relief-for-high-impact-chronic-pain-patients 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/large-clinical-study-finds-home-based-virtual-reality-device-creates-greater-relief-for-high-impact-chronic-pain-patients 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cardiofocus-announces-first-patients-treated-with-optishottm-pulsed-field-ablation-system 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiofocus-announces-first-patients-treated-with-optishottm-pulsed-field-ablation-system 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-s-diabetes-drug-study-shows-positive-results-despite-stock-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-s-diabetes-drug-study-shows-positive-results-despite-stock-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-link-between-hearing-loss-and-cognitive-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-link-between-hearing-loss-and-cognitive-decline 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lipocine-inc-advances-in-metabolic-and-endocrine-disorders-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipocine-inc-advances-in-metabolic-and-endocrine-disorders-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/guangshengtang-s-innovative-hepatitis-b-drug-included-in-breakthrough-therapy-list 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guangshengtang-s-innovative-hepatitis-b-drug-included-in-breakthrough-therapy-list 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biper-therapeutics-secures-eur800000-in-bridge-funding-for-gastrointestinal-cancer-treatment-development 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biper-therapeutics-secures-eur800000-in-bridge-funding-for-gastrointestinal-cancer-treatment-development 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-reports-positive-clinical-update-on-afm24-atezolizumab-combination-therapy-in-non-small-cell-lung-cancer-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/affimed-reports-positive-clinical-update-on-afm24-atezolizumab-combination-therapy-in-non-small-cell-lung-cancer-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-to-present-data-from-three-arms-of-its-ongoing-phase-2a-trial-of-imm-1-104-in-early-january-2025 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneering-to-present-data-from-three-arms-of-its-ongoing-phase-2a-trial-of-imm-1-104-in-early-january-2025 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/surgical-intervention-may-improve-survival-in-young-patients-with-breast-cancer 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surgical-intervention-may-improve-survival-in-young-patients-with-breast-cancer 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-crl-to-j-j-s-bla-for-subcutaneous-rybrevant-in-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-crl-to-j-j-s-bla-for-subcutaneous-rybrevant-in-nsclc 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fresenius-kabi-launches-epinephrine-injection-usp-expanding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fresenius-kabi-launches-epinephrine-injection-usp-expanding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-read-breast-cancer-articles-of-2024-highlight-advances-in-research-and-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-most-read-breast-cancer-articles-of-2024-highlight-advances-in-research-and-treatment 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-vaccine-insights-on-pregnancy-and-breastfeeding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-vaccine-insights-on-pregnancy-and-breastfeeding 2024-12-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sagimet-biosciences-up-30-on-strong-clinical-stage-data-mugglehead-magazine 2024-12-16T23:58:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sagimet-biosciences-up-30-on-strong-clinical-stage-data-mugglehead-magazine 2024-12-16T23:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-update-on-neoadjuvant-therapy-trials-in-rcc 2024-12-16T23:43:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/suo-2024-update-on-neoadjuvant-therapy-trials-in-rcc 2024-12-16T23:43:00+00:00 weekly 0.7 https://trial.medpath.com/news/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-in-3l-mcrc 2024-12-16T23:42:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-announces-first-patient-dosed-in-phase-2-trial-of-petosemtamab-in-3l-mcrc 2024-12-16T23:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-host-conference-call-to-announce-topline-results-from-phase-ii-covalent-111 2024-12-16T23:30:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-to-host-conference-call-to-announce-topline-results-from-phase-ii-covalent-111 2024-12-16T23:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-host-conference-call-to-announce-topline-globenewswire 2024-12-16T23:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-to-host-conference-call-to-announce-topline-globenewswire 2024-12-16T23:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/purpose-beyond-a-cure-advancing-hodgkin-lymphoma-treatment-uf-health 2024-12-16T22:50:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/purpose-beyond-a-cure-advancing-hodgkin-lymphoma-treatment-uf-health 2024-12-16T22:50:40+00:00 weekly 0.7 https://trial.medpath.com/news/prevail-therapeutics-seeking-to-bring-gene-therapy-pr001-to-parkinson-disease-cgtlive-r 2024-12-16T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prevail-therapeutics-seeking-to-bring-gene-therapy-pr001-to-parkinson-disease-cgtlive-r 2024-12-16T22:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-receive-kimmtrak-in-phase-3-uveal-melanoma-trial-cure-today 2024-12-16T22:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-receive-kimmtrak-in-phase-3-uveal-melanoma-trial-cure-today 2024-12-16T22:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/lehigh-valley-health-network-only-in-region-to-participate-in-drug-coated-balloon-clinical-trial 2024-12-16T22:17:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lehigh-valley-health-network-only-in-region-to-participate-in-drug-coated-balloon-clinical-trial 2024-12-16T22:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-therapeutics-corp-sec-10-q-report-tradingview 2024-12-16T22:01:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-therapeutics-corp-sec-10-q-report-tradingview 2024-12-16T22:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs 2024-12-16T21:34:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-provides-update-on-keyvibe-and-keyform-clinical-development-programs 2024-12-16T21:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/knight-therapeutics-announces-filing-of-new-drug-submission-for-qelbree-r-viloxazine-in-canada 2024-12-16T21:32:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/knight-therapeutics-announces-filing-of-new-drug-submission-for-qelbree-r-viloxazine-in-canada 2024-12-16T21:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/contineum-therapeutics-initiates-patient-dosing-in-phase-1b-pet-trial 2024-12-16T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contineum-therapeutics-initiates-patient-dosing-in-phase-1b-pet-trial 2024-12-16T21:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-explores-whether-cbd-can-reduce-scan-related-anxiety-in-patients-with-advanced 2024-12-16T20:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-explores-whether-cbd-can-reduce-scan-related-anxiety-in-patients-with-advanced 2024-12-16T20:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-s-swot-analysis-cell-therapy-stock-faces-pivotal-trial-phase-investing-com 2024-12-16T20:25:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-s-swot-analysis-cell-therapy-stock-faces-pivotal-trial-phase-investing-com 2024-12-16T20:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/national-trial-explores-light-therapy-for-parkinson-s-disease 2024-12-16T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/national-trial-explores-light-therapy-for-parkinson-s-disease 2024-12-16T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/q32-bio-pushes-back-phase-2-trial-of-adx-097-in-aav-patients-anca-vasculitis-news 2024-12-16T19:15:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q32-bio-pushes-back-phase-2-trial-of-adx-097-in-aav-patients-anca-vasculitis-news 2024-12-16T19:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-pr-newswire 2024-12-16T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-pr-newswire 2024-12-16T18:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/tracer-to-diagnose-parkinson-s-via-pet-scans-moving-into-clinical-trial 2024-12-16T18:15:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tracer-to-diagnose-parkinson-s-via-pet-scans-moving-into-clinical-trial 2024-12-16T18:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb 2024-12-16T18:01:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb 2024-12-16T18:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/mark-humayun-md-phd-discusses-advance-stem-cell-derived-therapies-for-dry-amd 2024-12-16T17:13:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mark-humayun-md-phd-discusses-advance-stem-cell-derived-therapies-for-dry-amd 2024-12-16T17:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/usf-health-launches-state-funded-hyperbaric-oxygen-therapy-trial-with-first-patient 2024-12-16T16:38:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usf-health-launches-state-funded-hyperbaric-oxygen-therapy-trial-with-first-patient 2024-12-16T16:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/reviva-announces-prel-topline-ole-data-of-phase-3-recover-study-of-brilaroxazine-in 2024-12-16T16:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reviva-announces-prel-topline-ole-data-of-phase-3-recover-study-of-brilaroxazine-in 2024-12-16T16:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-sildenafil-cream-for-fsad-maintained-across-patient-subgroups-urology-times 2024-12-16T16:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-of-sildenafil-cream-for-fsad-maintained-across-patient-subgroups-urology-times 2024-12-16T16:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/lib-therapeutics-submits-a-biologic-license-application-to-fda-for-lerodalcibep-for-biospace 2024-12-16T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lib-therapeutics-submits-a-biologic-license-application-to-fda-for-lerodalcibep-for-biospace 2024-12-16T16:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/why-the-investor-craze-for-ozempic-and-rival-weight-loss-drugs-may-resume-next-year 2024-12-16T15:34:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-the-investor-craze-for-ozempic-and-rival-weight-loss-drugs-may-resume-next-year 2024-12-16T15:34:30+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-may-reduce-unnecessary-prostate-cancer-biopsies-news-center 2024-12-16T15:30:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-test-may-reduce-unnecessary-prostate-cancer-biopsies-news-center 2024-12-16T15:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/3-closely-watched-drugs-that-failed-in-the-clinic-pharmavoice 2024-12-16T15:16:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-closely-watched-drugs-that-failed-in-the-clinic-pharmavoice 2024-12-16T15:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-jumps-after-snagging-fda-approval-for-a-first-in-decades-drug-yahoo 2024-12-16T15:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurocrine-jumps-after-snagging-fda-approval-for-a-first-in-decades-drug-yahoo 2024-12-16T15:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/arcutis-submits-snda-for-roflumilast-cream-0-05-to-fda-for-patients-ages-2-to-5-with 2024-12-16T15:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arcutis-submits-snda-for-roflumilast-cream-0-05-to-fda-for-patients-ages-2-to-5-with 2024-12-16T15:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-rekambys-the-first-and 2024-12-16T14:57:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-rekambys-the-first-and 2024-12-16T14:57:03+00:00 weekly 0.7 https://trial.medpath.com/news/genprex-s-reqorsa-advances-to-phase-2-after-successful-safety-trial-in-lung-cancer-treatment 2024-12-16T14:40:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genprex-s-reqorsa-advances-to-phase-2-after-successful-safety-trial-in-lung-cancer-treatment 2024-12-16T14:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-receives-approval-from-fda-for-the-proprietary-name-xyngari-tm 2024-12-16T14:20:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermata-receives-approval-from-fda-for-the-proprietary-name-xyngari-tm 2024-12-16T14:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/novel-dll3-targeted-bites-and-b7-h3-adcs-show-promise-in-extensive-stage-sclc-treatment 2024-12-16T14:15:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-dll3-targeted-bites-and-b7-h3-adcs-show-promise-in-extensive-stage-sclc-treatment 2024-12-16T14:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-trial-of-transcontm-hgh-lonapegsomatropin-in-globenewswire 2024-12-16T14:04:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-insights-trial-of-transcontm-hgh-lonapegsomatropin-in-globenewswire 2024-12-16T14:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/sifi-provides-updates-on-the-uk-and-us-regulatory-pathways-for-akantior-r-in-the-biospace 2024-12-16T13:57:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sifi-provides-updates-on-the-uk-and-us-regulatory-pathways-for-akantior-r-in-the-biospace 2024-12-16T13:57:31+00:00 weekly 0.7 https://trial.medpath.com/news/tharimmune-announces-phase-2-study-plan-for-th104-in-patients-with-moderate-to-severe 2024-12-16T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tharimmune-announces-phase-2-study-plan-for-th104-in-patients-with-moderate-to-severe 2024-12-16T13:55:28+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotech-secures-fda-rare-pediatric-disease-status-for-novel-brain-cancer-drug 2024-12-16T13:52:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotech-secures-fda-rare-pediatric-disease-status-for-novel-brain-cancer-drug 2024-12-16T13:52:22+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-explains-the-landscape-of-oncology-trials-in-brazil-clinical-leader 2024-12-16T13:52:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-explains-the-landscape-of-oncology-trials-in-brazil-clinical-leader 2024-12-16T13:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/beta-blockers-associated-with-delayed-onset-and-decreased-progression-of-huntington-s-disease 2024-12-16T13:51:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beta-blockers-associated-with-delayed-onset-and-decreased-progression-of-huntington-s-disease 2024-12-16T13:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-biospace 2024-12-16T13:45:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-biospace 2024-12-16T13:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-human-study-demonstrates-the-potential-of-the-reprieve-system-in-patients-with 2024-12-16T13:45:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-human-study-demonstrates-the-potential-of-the-reprieve-system-in-patients-with 2024-12-16T13:45:13+00:00 weekly 0.7 https://trial.medpath.com/news/histosonics-is-expanding-to-treat-pancreatic-tumors-massdevice 2024-12-16T13:27:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/histosonics-is-expanding-to-treat-pancreatic-tumors-massdevice 2024-12-16T13:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-gsk 2024-12-16T13:15:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-gsk 2024-12-16T13:15:44+00:00 weekly 0.7 https://trial.medpath.com/news/puretech-s-breakthrough-ipf-drug-shows-81-superior-efficacy-in-phase-2b-trial-results 2024-12-16T13:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puretech-s-breakthrough-ipf-drug-shows-81-superior-efficacy-in-phase-2b-trial-results 2024-12-16T13:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/pepgen-announces-clinical-hold-in-the-u-s-on-ind-application-to-initiate-connect2 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pepgen-announces-clinical-hold-in-the-u-s-on-ind-application-to-initiate-connect2 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/goldman-sachs-lifts-neurocrine-bio-shares-target-buy-rating-on-fda-approval 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/goldman-sachs-lifts-neurocrine-bio-shares-target-buy-rating-on-fda-approval 2024-12-16T13:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-announces-istaroxime-presentation-by-cardiogenic-globenewswire 2024-12-16T13:05:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/windtree-announces-istaroxime-presentation-by-cardiogenic-globenewswire 2024-12-16T13:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/dare-bioscience-announces-phase-3-plans-for-sildenafil-globenewswire 2024-12-16T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dare-bioscience-announces-phase-3-plans-for-sildenafil-globenewswire 2024-12-16T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/senti-bio-announces-first-patient-dosed-in-clinical-trial 2024-12-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senti-bio-announces-first-patient-dosed-in-clinical-trial 2024-12-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/scisparc-advances-11-6m-pharma-portfolio-spin-off-deal-with-miza-ventures-retaining 2024-12-16T12:58:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scisparc-advances-11-6m-pharma-portfolio-spin-off-deal-with-miza-ventures-retaining 2024-12-16T12:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/china-approves-merck-s-keytruda-to-treat-patients-with-resectable-stage-ii-iiia-or-iiib-nsclc 2024-12-16T12:57:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-approves-merck-s-keytruda-to-treat-patients-with-resectable-stage-ii-iiia-or-iiib-nsclc 2024-12-16T12:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-morningstar 2024-12-16T12:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-morningstar 2024-12-16T12:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/atsena-therapeutics-announces-dosing-completed-in-part-a-of-globenewswire 2024-12-16T12:31:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atsena-therapeutics-announces-dosing-completed-in-part-a-of-globenewswire 2024-12-16T12:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/roche-discontinues-hemophilia-a-gene-therapy-development-shifts-focus-to-enhanced-function-fviii-variant 2024-12-16T12:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-discontinues-hemophilia-a-gene-therapy-development-shifts-focus-to-enhanced-function-fviii-variant 2024-12-16T12:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/vectory-strengthens-leadership-team-with-appointment-of-jim-scibetta-as-new-ceo 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vectory-strengthens-leadership-team-with-appointment-of-jim-scibetta-as-new-ceo 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/foghorn-therapeutics-provides-update-on-fhd-286-clinical-development-program-and 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foghorn-therapeutics-provides-update-on-fhd-286-clinical-development-program-and 2024-12-16T12:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/2024-key-insights-skin-cancer-dermatology-times 2024-12-16T12:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-key-insights-skin-cancer-dermatology-times 2024-12-16T12:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents 2024-12-16T12:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents 2024-12-16T12:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/fluid-biomed-closes-27-million-usd-series-a-to-fund-expanded-human-clinical-studies 2024-12-16T12:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fluid-biomed-closes-27-million-usd-series-a-to-fund-expanded-human-clinical-studies 2024-12-16T12:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/caplin-steriles-receives-fda-approval-for-generic-difluprednate-eye-drops-ndtv-profit 2024-12-16T11:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caplin-steriles-receives-fda-approval-for-generic-difluprednate-eye-drops-ndtv-profit 2024-12-16T11:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-oncology-innovations-and-financial-growth-prospects 2024-12-16T11:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-oncology-innovations-and-financial-growth-prospects 2024-12-16T11:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-10-year-old-parker-girl-s-disease-is-one-in-a-million-the-colorado-sun 2024-12-16T11:26:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-10-year-old-parker-girl-s-disease-is-one-in-a-million-the-colorado-sun 2024-12-16T11:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/mannkind-s-inhaled-insulin-shows-promise-in-pivotal-pediatric-trial-eyes-fda-submission 2024-12-16T11:14:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mannkind-s-inhaled-insulin-shows-promise-in-pivotal-pediatric-trial-eyes-fda-submission 2024-12-16T11:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/study-supports-tamoxifen-for-dcis-early-breast-cancers 2024-12-16T11:12:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-supports-tamoxifen-for-dcis-early-breast-cancers 2024-12-16T11:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-announces-positive-topline-results-from-the-canyon-phase-2 2024-12-16T11:11:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edgewise-therapeutics-announces-positive-topline-results-from-the-canyon-phase-2 2024-12-16T11:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/medivir-s-ceo-to-biostock-the-ind-approval-is-a-very-important-milestone-cision-news 2024-12-16T10:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medivir-s-ceo-to-biostock-the-ind-approval-is-a-very-important-milestone-cision-news 2024-12-16T10:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/true-you-weight-loss-announces-two-clinical-trials-exploring-groundbreaking-non 2024-12-16T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/true-you-weight-loss-announces-two-clinical-trials-exploring-groundbreaking-non 2024-12-16T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/sinovac-launches-groundbreaking-phase-3-trial-for-first-global-multivalent-hfmd-vaccine 2024-12-16T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sinovac-launches-groundbreaking-phase-3-trial-for-first-global-multivalent-hfmd-vaccine 2024-12-16T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/incyclix-bio-reports-outcomes-from-breast-cancer-therapy-trial 2024-12-16T10:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyclix-bio-reports-outcomes-from-breast-cancer-therapy-trial 2024-12-16T10:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-treatment-option-now-available-in-lafayette 2024-12-16T10:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-treatment-option-now-available-in-lafayette 2024-12-16T10:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/accord-healthcare-is-granted-marketing-authorisation-for-imuldosa-r-ustekinumab 2024-12-16T10:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accord-healthcare-is-granted-marketing-authorisation-for-imuldosa-r-ustekinumab 2024-12-16T10:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/exercise-during-cancer-treatment-significantly-improves-survival-rates-in-breast-cancer-patients-roswell-park-study-shows 2024-12-16T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exercise-during-cancer-treatment-significantly-improves-survival-rates-in-breast-cancer-patients-roswell-park-study-shows 2024-12-16T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/danish-medicines-agency-seeks-eu-review-of-ozempic-over-risk-of-rare-vision-loss 2024-12-16T09:58:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/danish-medicines-agency-seeks-eu-review-of-ozempic-over-risk-of-rare-vision-loss 2024-12-16T09:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-receives-three-positive-regulatory-updates-on-cancer-products-shares-magazine 2024-12-16T09:38:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-receives-three-positive-regulatory-updates-on-cancer-products-shares-magazine 2024-12-16T09:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-ceo-bruce-cozadd-announces-retirement-after-15-year-tenure 2024-12-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-ceo-bruce-cozadd-announces-retirement-after-15-year-tenure 2024-12-16T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/assertio-therapeutics-receives-buy-rating-following-positive-clinical-trial-results 2024-12-16T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assertio-therapeutics-receives-buy-rating-following-positive-clinical-trial-results 2024-12-16T09:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/world-economic-forum-report-generative-ai-set-to-transform-clinical-trial-development 2024-12-16T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-economic-forum-report-generative-ai-set-to-transform-clinical-trial-development 2024-12-16T09:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/december-16-2024-study-snapshot-and-updated-ethics-documentation-available-for-i 2024-12-16T09:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/december-16-2024-study-snapshot-and-updated-ethics-documentation-available-for-i 2024-12-16T09:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-and-medicaid-see-dramatic-rise-in-rituximab-biosimilar-adoption-achieving-60-market-share-by-2022 2024-12-16T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-and-medicaid-see-dramatic-rise-in-rituximab-biosimilar-adoption-achieving-60-market-share-by-2022 2024-12-16T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shb-raises-target-price-for-egetis-therapeutics-to-sek-16-9-reiterates-buy 2024-12-16T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shb-raises-target-price-for-egetis-therapeutics-to-sek-16-9-reiterates-buy 2024-12-16T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/news/gh-research-awaits-topline-data-from-gh001-in-treatment-resistant-depression-trial 2024-12-16T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gh-research-awaits-topline-data-from-gh001-in-treatment-resistant-depression-trial 2024-12-16T08:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-sleep-disruption-among-parents-of-children-with-atopic-dermatitis 2024-12-16T08:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-significant-sleep-disruption-among-parents-of-children-with-atopic-dermatitis 2024-12-16T08:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/gerresheimer-fda-grants-tentative-approval-of-sq-innovation-s-lasix-r-onyu-eqs-news 2024-12-16T08:06:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gerresheimer-fda-grants-tentative-approval-of-sq-innovation-s-lasix-r-onyu-eqs-news 2024-12-16T08:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-secures-eur21-4-million-and-completes-the-first-globenewswire 2024-12-16T07:41:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-secures-eur21-4-million-and-completes-the-first-globenewswire 2024-12-16T07:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/exact-therapeutics-announces-fda-clearance-of-ind-for-enact-a-phase-2-trial-in 2024-12-16T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-therapeutics-announces-fda-clearance-of-ind-for-enact-a-phase-2-trial-in 2024-12-16T07:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-ema-priority-medicines 2024-12-16T07:15:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-ema-priority-medicines 2024-12-16T07:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/kraig-biocraft-doubles-spider-silk-gene-complexity-advancing-commercial-production-of-high-performance-biomaterials 2024-12-16T06:45:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kraig-biocraft-doubles-spider-silk-gene-complexity-advancing-commercial-production-of-high-performance-biomaterials 2024-12-16T06:45:20+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-acquires-global-rights-to-dualitybio-s-adc-in-milestone-for-nona-biosciences-collaboration-network 2024-12-16T06:26:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-acquires-global-rights-to-dualitybio-s-adc-in-milestone-for-nona-biosciences-collaboration-network 2024-12-16T06:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/relief-therapeutics-announces-final-readout-of-pku-golike-clinical-trial-stock-titan 2024-12-16T06:25:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relief-therapeutics-announces-final-readout-of-pku-golike-clinical-trial-stock-titan 2024-12-16T06:25:19+00:00 weekly 0.7 https://trial.medpath.com/news/cultural-understanding-key-to-addressing-ovarian-cancer-disparities-among-pacific-islanders-study-finds 2024-12-16T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cultural-understanding-key-to-addressing-ovarian-cancer-disparities-among-pacific-islanders-study-finds 2024-12-16T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-for-autoimmune-disease-gains-traction-drug-discovery-news 2024-12-16T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-for-autoimmune-disease-gains-traction-drug-discovery-news 2024-12-16T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-rises-10-after-antibiotic-zaynich-undergoing-clinical-trials-facilitates-in-a-liver-transplant 2024-12-16T04:32:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-rises-10-after-antibiotic-zaynich-undergoing-clinical-trials-facilitates-in-a-liver-transplant 2024-12-16T04:32:51+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-shares-add-to-their-220-gain-for-2024-with-another-10-surge-explained 2024-12-16T04:32:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-shares-add-to-their-220-gain-for-2024-with-another-10-surge-explained 2024-12-16T04:32:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-multiple-breakthrough-therapies-crenessity-for-cah-unloxcyt-for-skin-cancer 2024-12-16T03:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-multiple-breakthrough-therapies-crenessity-for-cah-unloxcyt-for-skin-cancer 2024-12-16T03:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-clinical-trial-landscape-shows-asia-pacific-leading-sclc-research-with-over-1200-studies-since-2019 2024-12-16T03:56:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-clinical-trial-landscape-shows-asia-pacific-leading-sclc-research-with-over-1200-studies-since-2019 2024-12-16T03:56:58+00:00 weekly 0.7 https://trial.medpath.com/news/hiro-forges-strategic-partnership-with-cha-university-bundang-medical-center-in-south-korea 2024-12-16T03:02:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hiro-forges-strategic-partnership-with-cha-university-bundang-medical-center-in-south-korea 2024-12-16T03:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/25-years-of-cgm-innovation-major-advances-mark-2024-as-breakthrough-year-for-glucose-monitoring 2024-12-16T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/25-years-of-cgm-innovation-major-advances-mark-2024-as-breakthrough-year-for-glucose-monitoring 2024-12-16T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-ecg-analysis-set-to-transform-pharmaceutical-drug-development-and-clinical-trials 2024-12-16T02:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-ecg-analysis-set-to-transform-pharmaceutical-drug-development-and-clinical-trials 2024-12-16T02:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/european-chmp-recommends-approval-for-four-celltrion-biosimilars-businesskorea 2024-12-16T02:18:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-chmp-recommends-approval-for-four-celltrion-biosimilars-businesskorea 2024-12-16T02:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/pharming-announces-public-cash-offer-to-the-shareholders-of-abliva-ab-stock-titan 2024-12-16T01:19:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharming-announces-public-cash-offer-to-the-shareholders-of-abliva-ab-stock-titan 2024-12-16T01:19:07+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-shr-1701-to-first-line-capecitabine-and-oxaliplatin-xelox-plus-bevacizumab 2024-12-16T01:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-shr-1701-to-first-line-capecitabine-and-oxaliplatin-xelox-plus-bevacizumab 2024-12-16T01:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/noninvasive-early-identification-of-durable-clinical-benefit-from-immune-checkpoint-inhibition 2024-12-16T01:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noninvasive-early-identification-of-durable-clinical-benefit-from-immune-checkpoint-inhibition 2024-12-16T01:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/hs-20093-b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hs-20093-b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority 2024-12-16T00:00:00+00:00 weekly 0.7